

10/582285

1

Keto lactam compounds and use thereof

AP3 Rec'd PCT/PTD 09 JUN 2005

Description

5 The present invention relates to novel keto lactam compounds, hydrogenated derivatives and tautomers thereof. These compounds possess valuable therapeutic properties and are suitable especially for the treatment of diseases which respond to the modulation of the dopamine D₃ receptor.

10 Neurons obtain their information from sources including G protein-coupled receptors. There are numerous substances which exert their action via these receptors. One of these is dopamine. Confirmed findings about the presence of dopamine and its physiological function as a neurotransmitter have been published. Disturbances in the dopaminergic transmitter system result in diseases of the central nervous system which include, for example, schizophrenia, depression or Parkinson's disease. One possible
15 treatment of these and other diseases is based on the administration of substances which interact with the dopamine receptors.


Up to 1990, two subtypes of dopamine receptors were clearly defined
20 pharmacologically, specifically the D₁ and D₂ receptors. More recently, a third subtype has been found, specifically the D₃ receptor, which appears to mediate some effects of antipsychotics and antiparkinsonian drugs (J.C. Schwartz et al., The Dopamine D₃ Receptor as a Target for Antipsychotics, in Novel Antipsychotic Drugs, H.Y. Meltzer, Ed. Raven Press, New York 1992, pages 135-144; M. Dooley et al., Drugs and Aging
25 1998, 12, 495-514, J.N. Joyce, Pharmacology and Therapeutics 2001, 90, p. 231-59 "The Dopamine D₃ Receptor as a Therapeutic Target for Antipsychotic and Antiparkinsonian Drugs").

The dopamine receptors are now divided into two families: firstly the D₂ group
30 consisting of D₂, D₃ and D₄ receptors, secondly the D₁ group consisting of D₁ and D₅ receptors. While D₁ and D₂ receptors are widespread, D₃ receptors, in contrast, appear to be expressed regioselectively. Thus, these receptors are found preferentially in the limbic system, the projection regions of the mesolimbic dopamine system, in particular in the nucleus accumbens, but also in other regions such as the amygdala. Owing to
35 this comparatively regioselective expression, D₃ receptors are considered to be a target with low side effects, and it is assumed that a selective D₃ ligand should have the properties of known antipsychotics but not their dopamine D₂ receptor-mediated neurological side effects (P. Sokoloff et al., Localization and Function of the D₃ Dopamine Receptor, *Arzneim. Forsch./Drug Res.* 42(1), 224 (1992); P. Sokoloff et al.
40 Molecular Cloning and Characterization of a Novel Dopamine Receptor (D₃) as a Target for Neuroleptics, *Nature*, 347, 146 (1990)).

Compounds having dopamine D₃ receptor affinity have been described variously in the prior art, for example, in WO 96/02519, WO 96/02520, WO 96/02249, WO 96/02246, WO 97/25324, WO 00/42036, DE 10131543 and WO 99/02503. Some of these compounds have high affinities for the dopamine D₃ receptor. They are therefore proposed for the treatment of diseases of the central nervous system.

However, there is a fundamental need to provide further compounds with dopamine D₃ receptor affinity, whether it be to improve the pharmacological binding profile or because the prior art compounds cause undesired side effects, have poor cerebral availability or only low bioavailability. It is therefore an object of the invention to provide further compounds which act as selective dopamine D₃ receptor ligands.

This object is achieved by the derivatives of keto lactams which have the general formula I




where

-A- is a group of the formulae or where D is bonded to the nitrogen atom and where

R^p and R^q are each independently selected from hydrogen, halogen, optionally substituted C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyloxy, C₃-C₆-cycloalkyl-C₁-C₄-alkyloxy and optionally substituted phenyl;

W is O, S or an N-R^z group where R^z is selected from optionally substituted C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyloxy, C₃-C₆-cycloalkyl-C₁-C₄-alkyloxy and optionally substituted phenyl

and * denotes the bonding sites;



-B- is a bond or where R^m and R^n are each independently selected from hydrogen, halogen, optionally substituted C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_1 - C_6 -alkoxy, C_3 - C_6 -cycloalkyloxy, C_3 - C_6 -cycloalkyl- C_1 - C_4 -alkyloxy and optionally substituted phenyl, or, when the nitrogen in the A group is bonded to B, may also be a carbonyl group, and * denotes the bonding sites;

----- represents a single bond or a double bond;


10 R^v, R^w are each independently hydrogen, halogen, optionally substituted C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_3 - C_6 -cycloalkyloxy, C_3 - C_6 -cycloalkyl- C_1 - C_4 -alkyloxy or C_3 - C_6 -cycloalkyl;

15 R^x, R^y are each independently hydrogen, halogen, optionally substituted C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_3 - C_6 -cycloalkyloxy, C_3 - C_6 -cycloalkyl- C_1 - C_4 -alkyloxy or C_3 - C_6 -cycloalkyl, or

20 R^x, R^y together with the carbon atoms to which they are bonded, may also form a fused phenyl ring or a fused 5- or 6-membered aromatic heterocycle which has 1, 2, 3 or 4 heteroatoms which are selected from N, O and S, where the fused phenyl ring and the fused aromatic heterocycle may have 1, 2 or 3 substituents which are selected from optionally substituted C_1 - C_6 -alkyl, CN, OR^1 , NR^2R^3 , NO_2 , SR^4 , SO_2R^4 , $SO_2NR^2R^3$, $CONR^2R^3$, $COOR^5$, COR^6 , C_1 - C_4 -haloalkoxy, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_2 - C_6 -alkenyloxy, C_2 - C_6 -alkynyloxy, C_3 - C_6 -cycloalkyl, C_3 - C_6 -cycloalkyloxy and halogen; where

30 R^1, R^2, R^3, R^4, R^5 and R^6 are each independently H, optionally substituted C_1 - C_6 -alkyl or optionally substituted phenyl, where R^3 may also be a COR^7 group where R^7 is hydrogen, optionally substituted C_1 - C_4 -alkyl or optionally substituted phenyl, where R^2 with R^3 may also together form a 5- or 6-membered, saturated or unsaturated carbocycle which may have a heteroatom selected from O, S and NR^8 as a ring member, where R^8 is hydrogen or C_1 - C_4 -alkyl,

35 D is a linear or branched 2- to 10-membered alkylene chain which may have, as chain members, a heteroatom group K which is selected from O, S, $S(O)$, $S(O)_2$, $N-R^8$, $CO-O$, $C(O)NR^8$, and/or 1 or 2 nonadjacent carbonyl groups and which may include a cycloalkanediyl group and/or may have a double or triple bond;



is a saturated or monounsaturated, monocyclic nitrogen heterocycle having from 5 to 8 ring members or a bicyclic saturated nitrogen heterocycle having from 7 to 12 ring members, where the mono- and the bicyclic nitrogen heterocycle optionally has, as a ring member, a further heteroatom selected from oxygen, sulfur or nitrogen, where the mono- or bicyclic nitrogen heterocycle may be unsubstituted or bears an R^a radical, where


R^a is C_1 - C_{10} -alkyl, C_2 - C_{10} -alkenyl, C_1 - C_{10} -alkoxycarbonyl, C_1 - C_{10} -alkylcarbonyl, C_1 - C_{10} -alkylsulfonyl, C_1 - C_{10} -cyanoalkyl, C_3 - C_{10} -cycloalkyl, C_3 - C_{10} -cycloalkyl- C_1 - C_4 -alkyl, C_3 - C_{10} -heterocycloalkyl- C_1 - C_4 -alkyl, C_3 - C_{10} -cycloalkylcarbonyl, C_3 - C_{10} -cycloalkylcarbonyl- C_1 - C_4 -alkyl, phenylcarbonyl, phenylcarbonyl- C_1 - C_4 -alkyl, phenoxycarbonyl, phenyl- C_1 - C_{10} -alkyloxycarbonyl, 3- to 8-membered heterocyclylcarbonyl or 3- to 8-membered heterocyclylcarbonyl- C_1 - C_4 -alkyl, where heterocyclyl in the aforementioned radicals may have one, two or three heteroatoms selected from S, O and N, and

where the last 6 radicals may have, on the heterocycle or on the phenyl ring, 1, 2 or 3 substituents R^b which are each independently selected from optionally substituted C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_3 - C_6 -cycloalkyl, C_4 - C_{10} -bicycloalkyl and C_6 - C_{10} -tricycloalkyl, where the last three groups may optionally be substituted by halogen or C_1 - C_4 -alkyl, halogen, CN, OR^1 , NR^2R^3 , NO_2 , SR^4 , SO_2R^5 , $CONR^2R^3$, $SO_2NR^2R^3$, $COOR^5$, COR^6 , $O-COR^6$, 5- or 6-membered heterocyclyl having 1, 2 or 3 heteroatoms selected from O, S and N, and phenyl, where phenyl and heterocyclyl in the last two substituents R^b may optionally bear one or two substituents which are each independently selected from C_1 - C_4 -alkyl, C_1 - C_4 -alkoxy, NR^2R^3 , CN, C_1 - C_2 -fluoroalkyl and halogen, and where 2 substituents R^b bonded to adjacent carbon atoms of the and halogen, and where 2 substituents R^b bonded to adjacent carbon atoms of the aromatic radical may together be C_3 - or C_4 -alkylene, or, together with the carbon atoms to which they are bonded, may be a fused-on, unsaturated 5- or 6-membered carbocycle or a 5- or 6-membered heterocycle having 1 or 2 nitrogen atoms as ring members; or

R^a is an E-Ar group wherein E is a bond or linear or branched alkylene having from 1 to 4 carbon atoms and in particular $(CH_2)_p$ where p is 0, 1, 2, 3 or 4, and Ar is selected from phenyl, naphthyl and 5- or 6-membered heteroaryl which has one, two or three heteroatoms se-


5

lected from S, O and N as ring members and which may optionally have 1, 2 or 3 of the aforementioned substituents R^b ; or




5

is a saturated monocyclic nitrogen heterocycle having from 5 to 7 ring atoms which bears a fused-on benzene ring of the formula



10


where * denotes the bonding sites to the saturated monocyclic heterocycle; R^c may be the same or different and is as defined for R^b , and n is 0, 1, 2 or 3;



where may optionally also have 1, 2, 3 or 4 further C_1 - C_4 -alkyl groups as substituents;

15

the physiologically acceptable acid addition salts of this compound and the tautomer of the formula I'



(I)

20

where R is halogen, an $O-R^1$ group where R^1 is as defined above, or an $O-C(O)R^9$ group where R^9 is hydrogen, optionally substituted C_1 - C_6 -alkyl, benzyl or phenyl, where the last two radicals are optionally substituted by one or two radicals which are each independently selected from C_1 - C_4 -alkyl, OH, C_1 - C_4 -alkoxy, NR^2R^3 , CN, C_1 - C_2 -fluoroalkyl or halogen, and the physiologically acceptable acid addition salts of the tautomer I'.

25

The present invention therefore provides the compounds of the general formula I, the tautomers of the formula I' and the physiologically tolerated acid addition salts of the compounds I and their tautomers I'.

30

The present invention also provides for the use of compounds of the general formula I, the tautomers of the formula I' and the physiologically tolerated acid addition salts of the compounds I and their tautomers I' for producing a pharmaceutical composition for

treating diseases which respond to the influence of dopamine D₃ receptor antagonists or agonists.

The diseases which respond to the influence of dopamine D₃ receptor antagonists or agonists include in particular disorders and diseases of the central nervous system, especially affective disorders, neurotic disorders, stress disorders and somatoform disorders and psychoses, specifically schizophrenia and depression and also renal function disorders, especially renal function disorders caused by diabetes mellitus (see WO 00/67847).

According to the invention, the aforementioned indications are treated by using at least one compound of the general formula I, a tautomer of the general formula I' or a physiologically tolerated acid addition salt of a compound I or of a tautomer I'. When the compounds of the formula I or their tautomers I' have one or more centers of asymmetry, it is also possible to employ mixtures of enantiomers, especially racemates, mixtures of diastereomers, mixtures of tautomers, but preferably the particular substantially pure enantiomers, diastereomers and tautomers.

It is likewise possible to use physiologically tolerated salts of the compounds of the formula I and of the tautomers I', in particular acid addition salts with physiologically tolerated acids. Examples of useful physiologically tolerated organic and inorganic acids include hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, C₁-C₄-alkylsulfonic acids such as methanesulfonic acid, aromatic sulfonic acids such as benzenesulfonic acid and toluenesulfonic acid, oxalic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, adipic acid and benzoic acid. Further acids which can be used are described in Fortschritte der Arzneimittelforschung, volume 10, pages 224 ff., Birkhäuser Verlag, Basle and Stuttgart, 1966.

Halogen here and hereinafter is fluorine, chlorine, bromine or iodine.

C_n-C_m-alkyl (including in radicals such as alkoxy, alkoxyalkyl, alkylthio, alkylamino, dialkylamino, alkylcarbonyl, etc.) is a straight-chain or branched alkyl group having n to m carbon atoms, for example 1 to 6 and especially 1 to 4 carbon atoms. Examples of an alkyl group are methyl, ethyl, n-propyl, isopropyl, n-butyl, 2-butyl, isobutyl, tert-butyl, n-pentyl, 2-pentyl, neopentyl, n-hexyl and the like.

The expression "optionally substituted C_n-C_m-alkyl" represents an alkyl radical which has from n to m carbon atoms, which may be partly or fully substituted by halogen, in particular by chlorine or fluorine, and which may have one or more, for example 1, 2 or 3, non-halogen substituents which are selected from halogen, CN, C₃-C₇-cycloalkyl, C₃-C₇-heterocycloalkyl, optionally substituted phenyl, OR¹¹, COOR¹¹, NR¹²R¹³,

7

$\text{SO}_2\text{NR}^{12}\text{R}^{13}$, $\text{CONR}^{12}\text{R}^{13}$, $\text{O-CONR}^{12}\text{R}^{13}$, S-R^{14} , SOR^{15} , SO_2R^{15} , OCOR^{16} and COR^{16} .

In these, R^{11} is as defined for R^1 , R^{12} is as defined for R^2 , R^{13} is as defined for R^3 , R^{14} is as defined for R^4 , R^{15} is as defined for R^5 and R^{16} is as defined for R^6 . In particular, R^{11}

- R^{16} are hydrogen, C_1 - C_4 -alkyl, C_1 - C_4 -haloalkyl, C_3 - C_7 -cycloalkyl, optionally substituted

5 benzyl or optionally substituted phenyl. Preferred substituents on alkyl are selected

from OH, C_1 - C_4 -alkoxy, halogen, C_3 - C_7 -cycloalkyl and optionally substituted phenyl. In

the case of OH, C_1 - C_4 -alkoxy, C_3 - C_7 -cycloalkyl and phenyl there is in particular only

one substituent. Such radicals are also referred to hereinafter as C_1 - C_6 -

alkyl such as methoxymethyl, 1- or 2-methoxyethyl, 1-methoxy-1-methylethyl or 2-

10 methoxy-1-methylethyl, 1-, 2- or 3-methoxypropyl, ethoxymethyl, 1- or 2-ethoxyethyl,

hydroxy- C_1 - C_6 -alkyl, 1-hydroxymethyl, 1- or 2-hydroxyethyl, 1-hydroxy-1-methylethyl, 1-

, 2- or 3-hydroxypropyl etc., C_3 - C_6 -cycloalkyl- C_1 - C_6 -alkyl such as cyclopropylmethyl,

cyclohexylmethyl or phenyl- C_1 - C_6 -alkyl. In the case of halogen substituents, these radi-

cals are also referred to as haloalkyl.

15

C_1 - C_6 -Haloalkyl (including in radicals such as C_1 - C_6 -haloalkoxy) represents an alkyl

group which has 1 to 6 and in particular 1 to 4 carbon atoms as defined above, in which

all or some, for example 1, 2, 3, 4 or 5, of the hydrogen atoms are replaced by halogen

atoms, in particular by chlorine or fluorine. Preferred haloalkyl is C_1 - C_2 -fluoroalkyl or C_1 -

20

C_2 -fluorochloroalkyl, in particular CF_3 , CHF_2 , CF_2Cl , CH_2F , CH_2CF_3 .

C_3 - C_{10} -cycloalkyl, including in radicals such as cycloalkylalkyl, cycloalkylcarbonyl and

cycloalkylcarbonylalkyl, represents a cycloaliphatic radical having 3 to 10 and prefera-

bly 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,

25

cycloheptyl and cyclooctyl.

C_3 - C_{10} -Heterocycloalkyl, including in radicals such as heterocycloalkylalkyl, hetero-

cycloalkylcarbonyl and heterocycloalkylcarbonylalkyl, represents a saturated hetero-

cyclic radical having ring members, where 1, 2 or 3 ring members are a heteroatom

30

selected from N, O and S, such as oxiranyl, oxetanyl, aziranyl, azetanyl, tetrahydrofur-

furyl, tetrahydrothienyl, pyrrolidinyl, pyrazolinyl, imidazolinyl, piperidinyl, piperazinyl or

morpholinyl.

C_4 - C_{10} -Bicycloalkyl represents a bicycloaliphatic radical having 4 to 10 carbon atoms as

35

in bicyclo[2.1.0]pentyl, bicyclo[2.1.1]hexyl, bicyclo[3.1.0]hexyl, bicyclo[2.2.1]heptanyl,

bicyclo[3.2.0]heptanyl, bicyclo[2.2.2]octanyl, bicyclo[3.2.1]octanyl, bicyclo[3.3.1]nonyl

and bicyclo[4.4.0]decyl.

C_6 - C_{10} -Tricycloalkyl represents a tricycloaliphatic radical having 6 to 10 carbon atoms

40

as in adamantyl.

C₂-C₆-alkenyl represents a monounsaturated linear or branched hydrocarbon radical having 2, 3, 4, 5 or 6 carbon atoms, for example vinyl, allyl (2-propen-1-yl), 1-propen-1-yl, 2-propen-2-yl, methallyl (2-methylprop-2-en-1-yl) and the like. C₃-C₄-alkenyl is in particular allyl, 1-methylprop-2-en-1-yl, 2-buten-1-yl, 3-buten-1-yl, methallyl, 2-penten-1-yl, 3-penten-1-yl, 4-penten-1-yl, 1-methylbut-2-en-1-yl, 2-ethylprop-2-en-1-yl.

C₂-C₆-Haloalkenyl represents an alkenyl group as defined above, in which all or some, for example 1, 2, 3, 4 or 5, of the hydrogen atoms are replaced by halogen atoms, in particular by chlorine or fluorine.

C₂-C₆-alkynyl represents a hydrocarbon radical having 2, 3, 4, 5 or 6 carbon atoms and having a triple bond, for example propargyl (2-propyn-1-yl), 1-methylprop-2-yn-1-yl, 2-butyne-1-yl, 3-butyne-1-yl, 2-pentyne-1-yl, 1-pentyne-3-yl, etc.

C₂-C₆-Haloalkynyl represents an alkenyl group as defined above, in which all or some, for example 1, 2, 3, 4 or 5, of the hydrogen atoms are replaced by halogen atoms, in particular by chlorine or fluorine.

phenyl-C₁-C₄-alkyl represents a C₁-C₄-alkyl radical as defined above, in which a hydrogen atom is replaced by a phenyl radical, as in benzyl or 2-phenylethyl.

Optionally substituted phenyl represents phenyl that optionally has one or more, for example 1, 2 or 3, of the following substituents: halogen, nitro, cyano, optionally substituted C₁-C₄-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, OR²¹, COOR²¹, NR²²R²³, SO₂NR²²R²³, CONR²²R²³, O-CONR²²R²³, S-R²⁴, SOR²⁵, SO₂R²⁵, OCOR²⁶ and COR²⁶. Examples of suitable substituents on phenyl are in particular halogen, C₁-C₄-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-alkoxy-C₁-C₄-alkyl, hydroxy-C₁-C₄-alkyl, hydroxy, nitro, NH₂, cyano, COOH, C₁-C₄-alkoxycarbonyl, C₁-C₄-alkylcarbonyl, C₁-C₄-alkylamino, di(C₁-C₄-alkyl)amino, C₁-C₄-alkylsulfonyl, C₁-C₄-alkylsulfonylamino and/or C₁-C₄-alkylaminosulfonyl. In these, R²¹ is as defined for R¹, R²² is as defined for R², R²³ is as defined for R³, R²⁴ is as defined for R⁴, R²⁵ is as defined for R⁵, and R²⁶ is as defined for R⁶. In particular, R²¹ - R²⁶ are hydrogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₃-C₇-cycloalkyl, optionally substituted benzyl or optionally substituted phenyl.

The term "alkylene" encompasses in principle straight-chain or branched radicals having preferably from 2 to 10 and more preferably from 3 to 8 carbon atoms such as prop-1,2-ylene, prop-1,3-ylene, but-1,2-ylene, but-1,3-ylene, but-1,4-ylene, 2-methylprop-1,3-ylene, pent-1,2-ylene, pent-1,3-ylene, pent-1,4-ylene, pent-1,5-ylene, pent-2,3-ylene, pent-2,4-ylene, 1-methylbut-1,4-ylene, 2-methylbut-1,4-ylene, hex-1,3-ylene, hex-2,4-ylene, hex-1,4-ylene, hex-1,5-ylene, hex-1,6-ylene and the like. C₀-alkylene

represents a single bond, C₁-alkylene represents methylene and C₂-alkylene represents 1,1-ethylene or 1,2-ethylene.

5 The term 3 to 8 membered heterocyclyl encompasses saturated (= heterocycloalkyl), partly unsaturated heterocyclic radicals and aromatic heterocycles (heteroaryl) of ring size 3, 4, 5, 6, 7 and 8, in particular of ring size 5 or 6, having 1, 2 or 3 heteroatoms as ring members. The heteroatoms in this case are selected from O, S and N.

10 Examples of saturated 3- to 8-membered heterocyclyl are oxiranyl, oxetanyl, aziranyl, piperidiny, piperaziny, morpholiny, pyrrolidiny, oxazolidiny, tetrahydrofuryl, di-oxolanyl, dioxanyl, hexahydroazepiny, hexahydrooxepiny, and hexahydrothiepinyl.

15 Examples of partly unsaturated 3- to 8-membered heterocyclyl are di- and tetrahydro-pyridiny, pyrroliny, oxazoliny, dihydrofuryl, tetrahydroazepiny, tetrahydrooxepiny, and tetrahydrothiepinyl.


20 Examples of 5-membered heteroaromatic radicals (= 5-membered heteroaryl) are those having 1, 2, 3 or 4 heteroatoms as ring members which are selected independently of one another from O, N and S, for example pyrrole, thiophene, furan, oxazole, isoxazole, selected from O, N and S, for example pyrrole, thiophene, furan, oxazole, isoxazole, thiazole, isothiazole, imidazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,3,4-thiadiazole, 1,2,3-triazole, 1,2,4-triazole, 1,3,4-triazole, tetrazole. Examples of 6-membered heteroaromatic radicals (= 6-membered heteroaryl) having 1 or 2 nitrogen atoms as ring members are in particular 2-, 3- or 4-pyridiny, 2-, 4- or 5-pyrimidiny, 2- or 3-pyraziny and 3- or 4-pyridaziny. The 6-membered heteroaromatic radicals may have the substituents specified above and/or be fused with a nonaromatic or aromatic carbocycle, in particular a benzene or cyclohexene ring as in benzo[b]pyridine (= quinoline), benzo[c]pyridine (isoquinoline), benzo[b]pyrimidine (quinazoline), cinnoline, phthalazine or quinoxaline. In the 5- or 6-membered heteroaromatic Ar radicals, 30 the bonding to the (CH₂)_p group is preferably via a carbon atom.

35 In connection with the D group, the two bonding sites of the alkylene chain are generally not on the same carbon atom but rather form, optionally together with the heteroatom group K and/or the carbonyl group, an at least two-, preferably at least three- and in particular at least four-membered chain which separates the nitrogen atom in the A group from the nitrogen atom of the nitrogen heterocycle NZ by at least 3, preferably by at least 4 and in particular by at least 5 bonds from one another. When D has no carbonyl group and no heteroatom group K, D comprises preferably from 3 to 10 carbon atoms, in particular from 4 to 8 carbon atoms and more preferably from 4 to 6 carbon atoms as chain members. The chain between the atom A and the nitrogen atom of NZ 40 then has at least 3 and in particular at least 4 carbon atoms. When D has a carbonyl

group or a heteroatom group K, D comprises, in addition to these groups, generally from 1 to 10 carbon atoms, in particular from 2 to 8 carbon atoms and especially from 3 to 5 carbon atoms as chain members. The number of chain members including the K group and/or the carbonyl group is selected such that the nitrogen atom in the A group is separated from the nitrogen atom of the nitrogen heterocycle NZ by at least 3, preferably by at least 4 and in particular by at least 5 bonds from one another. Moreover, the saturated C-C bonds in alkylene may be replaced by unsaturated bonds (alkenylene; alkynylene). Thus, straight-chain or branched unsaturated radicals can arise, whose number and arrangement of the carbon atoms corresponds to that of the aforementioned alkylene radicals, except that one or more single bonds have been replaced by corresponding unsaturated double or triple bonds. Also, D may comprise a cycloalkanediyl radical, preferably a C₃-C₇-cycloalkanediyl radical, in particular a C₄-C₇-cycloalkane-1,2-, -1,3- or -1,4-diyl radical, for example cyclopropane-1,2-diyl, cyclobutane-1,2- or -1,3-diyl, cyclopentane-1,2- or -1,3-diyl, cyclohexane-1,2-, -1,3- or -1,4-diyl radical, or a cycloheptane-1,2-, -1,3- or 1,4-diyl radical. This cycloalkanediyl radical is part of the chain D. In other words, some of the cycloalkanediyl radicals form the chain D with the remaining chain members, the smaller part of the cycloalkanediyl radical being crucial with regard to the separation of the nitrogen atoms into B and NZ.

When the alkylene group in D comprises at least one heteroatom, a heteroatom group K and/or a carbonyl group, these may be arranged in any position in the alkylene chain. The heteroatom is preferably not bonded to the nitrogen atom of the A group or to the nitrogen atom of NZ. A carbonyl group is preferably bonded to the nitrogen atom of the A group or to the nitrogen atom of the NZ group.


Examples of suitable D groups are: (CH₂)_k where k = 2, 3, 4, 5, 6, 7, 8, 9 or 10, CH(CH₃)(CH₂)_l with l = 1, 2, 3, 4, 5, 6, 7, 8 or 9, CH₂CH(CH₃)(CH₂)_{k'} with k' = 0, 1, 2, 3, 4, 5, 6, 7 or 8, *cis*- and *trans*-CH₂-CH=CH-CH₂, CH₂-C(CH₃)=CH-CH₂, CH₂CH₂CH=CHCH₂, CH₂CH₂C(CH₃)=CHCH₂, CH₂C(=CH₂)CH₂, CH₂CH₂CH(CH₃)CH₂, C(O)(CH₂)_l, C(O)-CH₂CH=CHCH₂, C(O)-CH₂C(CH₃)=CHCH₂, C(O)-CH₂C(=CH₂)CH₂, C(O)-CH₂CH(CH₃)CH₂,




CH₂-O-CH₂-CH₂, CH₂-O-CH₂-CH₂-CH₂, -CH₂-CH₂-O-CH₂-CH₂-, C(O)O-CH₂, C(O)O-CH₂CH₂, C(O)-O-CH₂CH₂CH₂, C(O)-O-CH₂CH=CHCH₂, C(O)-O-CH₂C(CH₃)=CHCH₂, C(O)-O-CH₂C(=CH₂)CH₂, C(O)-O-CH(CH₃)CH₂ and C(O)-O-CH₂CH(CH₃)CH₂.

11

- With regard to the use of the inventive compounds as dopamine D₃ receptor ligands, particular preference is given to those compounds I where D in formula I or I' is C₃-C₁₀-alkylene, in particular C₄-C₈-alkylene and especially C₄-C₆-alkylene, which may have a double bond, or C(O)C₂-C₉-alkylene, in particular C(O)C₃-C₈-alkylene and especially C(O)C₃-C₅-alkylene, which may have a double bond. In particular, D is a (CH₂)_k group or a C(O)(CH₂)_l, where k and l are each independently as defined above and are in particular each an integer from 3 to 8. More preferably, k is 4, 5 or 6 and l is 3, 4 or 5.

- When A is a  group or B is a carbonyl group, D is preferably C₃-C₁₀-alkylene, in particular C₄-C₈-alkylene and especially C₄-C₆-alkylene, which may have a double bond, especially C₄-C₆-alkylene which may have a double bond, and especially (CH₂)_k where k is as defined above, in particular as defined above with preference.


W is in particular oxygen.


- When A is , D is preferably a C(O)C₂-C₉-alkylene group, in particular C(O)C₃-C₈-alkylene, which may have a double bond. In particular D is a C(O)(CH₂)_l, where l is as defined above and is in particular 3, 4 or 5.

- In a first embodiment of the invention, B in the formulae I and I' is a carbonyl group or a CR^mRⁿ group, where R^m and Rⁿ are each as defined above and are in particular hydrogen or C₁-C₄-alkyl. In particular, at least one of the R^m or Rⁿ radicals and especially both R^m and Rⁿ radicals are hydrogen.

- In a second embodiment of the invention, B in the formulae I and I' is a bond.

With regard to the use of the inventive compounds I and I' as dopamine D₃ receptor ligands, preference is given to those compounds I and I' where the nitrogen atom of the A group is joined to the carbon atom which bears the R^x group.


- In particular, A is a group of the formula .


When A is a group of the formula , R^p and R^q are each independently in particular hydrogen or C₁-C₄-alkyl. In particular, at least one of the R^p or R^q radicals and especially both R^p and R^q radicals are hydrogen.

The R^v and R^w radicals are each independently hydrogen or C_1 - C_4 -alkyl. In particular, at least one of the R^v or R^w radicals and especially both R^v and R^w radicals are hydrogen.





- 5 Among the compounds of the formula I, preference is given to those compounds where R^x and R^y , together with the carbon atoms to which they are bonded, are a fused benzene ring or a fused 5- or 6-membered aromatic heterocycle which has 1, 2, 3 or 4 heteroatoms which are selected from N, O and S, where the fused phenyl ring and the fused aromatic heterocycle may have 1, 2 or 3 substituents which are selected from
- 10 C_1 - C_4 -alkyl, C_1 - C_4 -hydroxyalkyl, C_1 - C_4 -alkoxy- C_1 - C_4 -alkyl, CN, OR^1 , NR^2R^3 , NO_2 , SR^4 , SO_2R^4 , $SO_2NR^2R^3$, $CONR^2R^3$, $COOR^5$, COR^6 , C_1 - C_2 -fluoroalkyl, C_1 - C_2 -fluoroalkoxy, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_2 - C_6 -alkenyloxy, C_2 - C_6 -alkynyloxy, C_3 - C_6 -cycloalkyl, C_3 - C_6 -cycloalkyl and halogen; where R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are each independently as defined above. Preferred substituents are C_1 - C_4 -alkyl, C_1 - C_4 -haloalkyl, C_1 - C_4 -alkoxy and halogen. Among these, preference is given in particular to those compounds of the
- 15 formula I where R^x and R^y , together with the carbon atoms to which they are bonded, are a fused benzene ring optionally substituted in the manner described above.

- In another embodiment of the invention, R^x and R^y are each independently hydrogen, C_1 - C_6 -alkyl which is optionally substituted by OH, halogen, CN, C_1 - C_4 -alkoxy or optionally substituted phenyl, C_1 - C_6 -alkoxy, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl or C_3 - C_6 -cycloalkyl, and in particular hydrogen or C_1 - C_4 -alkyl. In that case, the bond ----- is in particular a single bond.
- 20











- 25 The groups of the formula , also referred to hereinafter as NZ, are a saturated or monounsaturated, mono- or bicyclic nitrogen heterocycle which optionally comprises a further heteroatom which is selected from nitrogen, oxygen and sulfur as a ring member. In the case of the bicyclic groups NZ, the two rings forming the bicyclic system are typically each independently 4-, 5-, 6- or 7-membered, the total number of
- 30 ring members being in the range from 7 to 12. The NZ group may have an R^a group or a fused-on benzene ring which may in turn be substituted in the manner described above. In addition, NZ may be a one, two, three or four further C_1 - C_4 -alkyl groups, in particular methyl groups.
- 35 Examples of suitable NZ groups are the mono- and bicyclic radicals NZ-1 to NZ-24 specified below.









13







5



10



15



20 In the NZ-1 to NZ-24 radicals, $R^{a'}$ is hydrogen or is as defined above for R^a . The variable q is 0, 1, 2, 3 or 4, in particular 0 or 1, and Alk is an alkyl group having from 1 to 4 carbon atoms. Among the NZ radicals, preference is given to monocyclic radicals.


When R^a is an R^a radical other than hydrogen, R^a in the radicals NZ-3 to NZ-5 and NZ-7 to NZ-15 is arranged in the 4- or in the 5-position based on the nitrogen atom which is bonded to D. In the bicyclic radicals NZ-16 to NZ-24, when $q \neq 0$, Alk may be arranged on one or both of the rings.

5

With regard to the use of the inventive compounds for modulating the dopamine D_3 receptor, preference is given to those compounds where NZ has an R^a group, and among these in particular monocyclic NZ radicals which have an R^a group.

10 With regard to the use of the inventive compounds as dopamine D_3 receptor ligands, particular preference is given to those compounds I where the NZ group, as an R^a radical, has an E-Ar radical and in particular a $(CH_2)_p$ -Ar radical. In these, Ar and E are each as defined above, and p is 0, 1, 2, 3 or 4 and in particular 0 or 1.

15 Among the inventive compounds I and I' in which the NZ group has, as the R^a radical, a group of the formula $(CH_2)_p$ -Ar, preference is given in particular to those compounds where $p = 0$ and Ar is phenyl, pyridyl, pyrimidinyl or s-triazinyl, which have 1, 2 or 3 of the aforementioned R^b radicals. In particular, Ar is then a radical of the formula Ar-1



Ar-1

20

where the variables D^1 to D^3 are each independently N, CH or $C-R^b$. In this, R^b has one of the definitions specified above. R^f and R^g are each independently hydrogen or have one of the definitions specified for R^b .

25 In a first preferred embodiment of the invention, at least one of the variables D^1 to D^3 in formula Ar-1 is N and the remaining variables are each CH, where one of the variables D^1 to D^3 may also be $C-R^b$ when one of the variables R^f is hydrogen. Among these, preference is given to compounds I and I' where D^1 , and especially D^1 and D^2 , are nitrogen and the remaining variables are each CH. In this embodiment, R^f and R^g are preferably each independently the following groups: hydrogen, OR^1 , NR^2R^3 , CN, C_1 - C_6 -alkyl which is optionally substituted by OH, C_1 - C_4 -alkoxy, halogen or phenyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_3 - C_6 -cycloalkyl, C_4 - C_{10} -bicycloalkyl, C_6 - C_{10} -tricycloalkyl, where the last three groups may optionally be substituted by halogen or C_1 - C_4 -alkyl, halogen, CN, OR^1 , 5- or 6-membered heterocyclyl having 1, 2 or 3 heteroatoms selected from O, S and N, and phenyl, where phenyl and heterocyclyl optionally bear one or two substituents which are each independently selected from C_1 - C_4 -alkyl, C_1 - C_4 -alkoxy, NR^2R^3 , CN, C_1 - C_2 -fluoroalkyl and halogen. R^x is preferably different from hydrogen. In particular, both R^f and R^g are different from hydrogen. In particular, R^f is C_1 - C_6 -alkyl, more

30

35

15

preferably branched C₃-C₆-alkyl and especially tert-butyl. R^g is preferably selected from C₁-C₄-alkyl, C₃-C₆-cycloalkyl and C₁-C₂-fluoroalkyl. More preferably, R^f and R^g both have the definitions specified as preferred.

- 5 In another embodiment of the invention, all variables D¹ to D³ in Ar-1 are CH or a C-R^b group. In this embodiment, R^f, R^g and R^b are each preferably selected from hydrogen, OR¹, NR²R³, CN, C₁-C₆-alkyl which is optionally substituted by OH, C₁-C₄-alkoxy, halogen or phenyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₄-C₁₀-bicycloalkyl, C₆-C₁₀-tricycloalkyl, where the last three groups may optionally be substituted by halogen
- 10 or C₁-C₄-alkyl, halogen, CN, OR¹, 5- or 6-membered heterocyclyl having 1, 2 or 3 heteroatoms selected from O, S and N, and phenyl, where phenyl and heterocyclyl optionally bear one or two substituents which are each independently selected from C₁-C₄-alkyl, C₁-C₄-alkoxy, NR²R³, CN, C₁-C₂-fluoroalkyl and halogen. In that case, Ar-1 more preferably has at least one substituent other than hydrogen. In this case, preferred substituents other than hydrogen are selected from halogen, especially chlorine
- 15 or fluorine, C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-haloalkoxy and CN. In a particularly preferred embodiment, Ar-1 is then 2,3-dichlorophenyl.
- 20 Among the inventive compounds I and I', in which the NZ group has an R^a radical of the formula (CH₂)_p-Ar, preference is further given to those compounds where p = 1 and Ar is as defined above. In particular, Ar is phenyl, naphthyl, pyridyl, pyridinyl, pyrazinyl, pyridazinyl, thienyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1-oxa-3,4-diazolyl or 1-thia-3,4-diazolyl, which are unsubstituted or may
- 25 have 1, 2 or 3 of the abovementioned R^b radicals. In that case, Ar is especially phenyl, pyridyl, thiadiazolyl, thienyl or imidazolyl, which may have 1, 2 or 3 of the abovementioned R^b radicals. In that case, preferred R^b radicals are in particular halogen, especially chlorine or fluorine, nitro, cyano, C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkyl and/or C₁-C₄-haloalkoxy.
- 30 In the compounds I in which NZ bears a radical of the formula E-Ar, Ar, when it is phenyl, or a heteroaromatic radical, may also be fused with an aromatic or heteroaromatic 5- or 6-membered cyclic system of the type mentioned above, for example with a 5- or 6-membered aromatic or nonaromatic heterocycle which has 1, 2 or 3 heteroatoms
- 35 selected from O, N and S, for example with pyridine, pyrimidine, pyrazine, pyridazine, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, 1,4-dioxane, 1,4-oxazinane or 1,3-dioxolane, such as in quinoline, isoquinoline, 4H-quinolizine, 1,5-, 1,6-, 1,7-, 1,8-, 2,6- or 2,7-naphthyridine, indole, indolizine, 1- or 2-benzofuran, 1- or 2-benzothiophene, 1,3-benzoxazole, benzo[1,2-b and 1,2-c]oxazole, 1,3-benzothiazole,
- 40 1,3-benzimidazole, benzo[1,2-b and 1,2-c]isothiazole, quinazoline, chromene, chroman, 1,4-benzopiperazine, 1- or 2-benzopiperidine, benzo[1,4-b]oxazinane, benzo[1,3-


16

b]dioxolane or benzo[1,4-b]dioxane. Phenyl and the aromatic heterocycles, especially phenyl and pyridyl, may also be fused with a 5- or 6-membered carbocycle, for example with benzene, cyclohex(adi)ene, cyclopent(adi)ene, such as in naphthalene, indane, indene, quinoline, isoquinoline, di- or tetrahydronaphthalene. In such radicals, the
 5 bonding of Ar is via the phenyl, pyridyl or pyrimidinyl moiety of the bicyclic radical.

Preference is likewise given to R^a groups which are selected from nonaromatic hydrocarbon radicals having from 1 to 14 carbon atoms, in particular C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₃-C₁₀-cycloalkyl, C₃-C₁₀-cycloalkyl-C₁-C₄-alkyl, C₃-C₁₀-cycloalkylcarbonyl-C₁-C₄-alkyl, C₃-C₁₀-heterocycloalkyl-C₁-C₄-alkyl and C₃-C₁₀-heterocycloalkylcarbonyl-C₁-C₄-alkyl. C₃-C₁₀-Cycloalkyl is then in particular cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. The same applies to the C₃-C₁₀-cycloalkyl-C₁-C₄-alkyl and C₃-C₁₀-cycloalkylcarbonyl-C₁-C₄-alkyl radicals. C₃-C₁₀-Heterocycloalkyl is then in particular tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, piperidinyl or morpholinyl. The same
 10 applies to the C₃-C₁₀-heterocycloalkyl-C₁-C₄-alkyl and C₃-C₁₀-heterocycloalkylcarbonyl-C₁-C₄-alkyl radicals. In this embodiment, particular preference is given to compounds where R^a is C₁-C₄-alkyl.

In particular, the NZ radicals obey the formula:

20



where

R^a is as defined above and in particular as defined above with preference;

25

J is CH₂, CH₂-CH₂ or CH₂-CH₂-CH₂, and in particular CH₂-CH₂;

X is CH or N and


30 Y is CH₂, CH₂-CH₂ or CH₂-CH₂-CH₂, or Y-X together are CH=C or CH₂-CH=C, preference being given to those radicals where X is N;

R^e is hydrogen or C₁-C₄-alkyl and in particular hydrogen.

35 Examples of such radicals are the aforementioned NZ-1, NZ-3 to NZ-15 radicals, among which particular preference is given to the NZ-3, NZ-4 and NZ-5 radicals. Most preferably, NZ is the NZ-5 radical.


17

In a first preferred embodiment of the invention, NZ is a radical of the formula NZ-A



- 5 where J, X, Y, R^e and Ar are each as defined above and in particular as defined above with preference, and Ar is in particular Ar-1.

In a second preferred embodiment of the invention, NZ is a radical of the formula NZ-B




10

- where J, X, Y, R^e and Ar are each as defined above and in particular as defined above with preference. In particular, Ar is phenyl, naphthyl, pyridyl, pyridinyl, pyrazinyl, pyridazinyl, thienyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1-oxa-3,4-diazolyl or 1-thia-3,4-diazolyl, which are unsubstituted or may have 1, 2 or 3 of the abovementioned R^b radicals. Ar is then especially phenyl, pyridyl, thienyl or imidazolyl, which may have 1, 2 or 3 of the abovementioned R^b radicals. Preferred R^b are then in particular halogen, especially chlorine or fluorine, nitro, cyano, C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkyl and/or C₁-C₄-haloalkoxy.

20

In a further preferred embodiment of the invention, NZ is a radical of the formula NZ-C




- 25 where R^e, J, X and Y are each as defined above and R^{aa} is a nonaromatic hydrocarbon radical having from 1 to 14 carbon atoms, in particular C₁-C₁₀-alkyl, C₂-C₁₀-alkenyl, C₃-C₁₀-cycloalkyl, C₃-C₁₀-cycloalkyl-C₁-C₄-alkyl, C₃-C₁₀-cycloalkylcarbonyl-C₁-C₄-alkyl, C₃-C₁₀-heterocycloalkyl-C₁-C₄-alkyl or C₃-C₁₀-heterocycloalkylcarbonyl-C₁-C₄-alkyl. C₃-C₁₀-Cycloalkyl is then in particular cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. The same applies to the C₃-C₁₀-cycloalkyl-C₁-C₄-alkyl and C₃-C₁₀-cycloalkylcarbonyl-C₁-C₄-alkyl radicals. C₃-C₁₀-Heterocycloalkyl is then in particular tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, piperidinyl or morpholinyl. The same applies to the C₃-C₁₀-

30


heterocycloalkyl-C₁-C₄-alkyl and C₃-C₁₀-heterocycloalkylcarbonyl-C₁-C₄-alkyl radicals. In this embodiment, particular preference is given to compounds where R^a is C₁-C₄-alkyl.

- 5 In a further embodiment of the invention, the NZ group bears a fused-on benzene ring of the formula



- 10 In this formula, n is preferably 1 or 2. R^a is preferably as defined for R^b and is in particular C₁-C₄-alkyl, C₁-C₄-alkoxy, CN, OR¹, NR²R³, NO₂, SR⁴, SO₂R⁴, SO₂NR²R³, COOR⁵, COR⁶, C₁-C₂-fluoroalkyl and halogen and especially C₁-C₄-alkyl, C₁-C₄-alkoxy, CN, COR⁶, C₁-C₂-fluoroalkyl and halogen.

In particular, the NZ group is then a radical of the formula NZ-D



15 where n and R^c are each as defined above,


J' is CH₂ or CH₂-CH₂;

- 20 Y' is a bond or CH₂ and


R^e is hydrogen or C₁-C₄-alkyl.

In the compounds of the formula I, the group of the formula


25



is preferably one of the A or B groups specified below:



(A)




(B)


- In formula A, the variables A and B are each as defined above, in particular as defined above with preference. In particular, the variable A in formula A is N-C(O), where the carbon atom is bonded to the variable B. B in formula A is in particular CH₂. The variable m is 0, 1, 2 or 3, in particular 0 or 1. R^d is independently C₁-C₄-alkyl, C₁-C₄-hydroxyalkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, CN, OR¹, NR²R³, NO₂, SR⁴, SO₂R⁴, SO₂NR²R³, CONR²R³, COOR⁵, COR⁶, C₁-C₂-fluoroalkyl, C₁-C₂-fluoroalkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₂-C₆-alkenyloxy, C₂-C₆-alkynyloxy, C₃-C₆-cycloalkyl, C₃-C₆-cycloalkyl or halogen, and is in particular selected from C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₂-fluoroalkyl and halogen. Compounds of the general formula I or their tautomers I' which have an A group are also referred to hereinafter as compounds I-A or I-A'.

- In Formel B, R^{x1} and R^{y1} are each independently hydrogen, halogen, optionally substituted C₁-C₆-alkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyloxy, C₃-C₆-cycloalkyl-C₁-C₄-alkyloxy or C₃-C₆-cycloalkyl, and in particular hydrogen or alkyl. Compounds of the general formula I or their tautomers I' which have a B group are also referred to hereinafter as compounds I-B or I-B'.


- Among the groups of the formulae A, mention should be made in particular of the A1, A2 and A3 groups:



(A1)



(A2)





(A3)

- In the formulae A1, A2 and A3, the variables m and R^d are each as defined above, in particular as defined above with preference. In formula A1, R^m and Rⁿ are each as defined above and in particular as defined above with preference. In particular, at least one of the R^m or Rⁿ radicals and especially both R^m and Rⁿ radicals are hydrogen. B' is CR^pR^q or CO, where R^p and R^q are each as defined above and in particular as defined above with preference. In particular, B' is CO. In formula A3, B is as defined above and is in particular CO or CH₂. Among the compounds IA or the tautomers IA', prefer-

20

ence is given in particular to those compounds which have, as the A group, a group of the formula A1 or A2.

Among the compounds of the formula IA, a preferred embodiment relates to compounds of the formula I-Aa defined below and its tautomers I-Aa':



10

In the formulae I-Aa and I-Aa', A, B, D, m, J, X, Y, R, R^a and R^d are each as defined above and in particular as defined above with preference.

15

In particular, J in the formulae I-Aa and I-Aa' is CH_2-CH_2 . The variable X in the formulae I-Aa and I-Aa' is in particular N, and Y is in particular CH_2 .

20

Among the compounds I-Aa and I-Aa', particular preference is given to those where D is a $(CH_2)_k$ or a $C(O)(CH_2)_l$ group, where k and l are each as defined above, where k is in particular 4, 5 or 6 and l is in particular 3, 4 or 5.

Among the compounds I-Aa and I-Aa', particular preference is given to those where A is $N-C(O)$, where the carbon atom is bonded to the variable B.

25

Among the compounds I-Aa and I-Aa', particular preference is given to those where B is CH_2 .

Among the compounds I-Aa and I-Aa', particular preference is given to those where R^a is an E-A group and in particular $(CH_2)_p-Ar$, where E, p and Ar are each as defined above, where, in particular, $p = 0$ or 1.


30

When $p = 0$, Ar is in particular as defined in connection with the NZ-A group. When $p = 1$, Ar is in particular as defined in connection with the NZ-B group. Among the com-

21

pounds I-Aa and I-Aa', preference is further given to those where R^a is a nonaromatic hydrocarbon radical having from 1 to 14 carbon atoms. R^a is then in particular as defined for R^{aa} in the NZ-C group.

- 5 Among the compounds of the formula I-B, a preferred embodiment relates to compounds of the formula I-Ba defined below and its tautomers:



- 10 In formula I-Ba, A, B, D, m, J, X, Y, R, R^a , R^{x1} and R^{y1} are each as defined above and in particular as defined above with preference.

In particular, J in formula I-Ba is $\text{CH}_2\text{-CH}_2$. The variable X in the formulae I-Aa and I-Aa' is in particular N, and Y is in particular CH_2 .

15

Among the compounds I-Ba, particular preference is given to those where D is a $(\text{CH}_2)_k$ group or a $\text{C}(\text{O})(\text{CH}_2)_l$, where k and l are each as defined above, where k is in particular 4, 5 or 6 and l is in particular 3, 4 or 5.

20


Among the compounds I-Ba, particular preference is given to those where R^a is an E-A group and in particular $(\text{CH}_2)_p\text{-Ar}$, where E, p and Ar are each as defined above, where, in particular, $p = 0$ or 1.

25

When $p = 0$, Ar is in particular as defined in connection with the NZ-A group. When $p = 1$, Ar is in particular as defined in connection with the NZ-B group. Among the compounds I-Aa and I-Aa', preference is further given to those where R^a is a nonaromatic hydrocarbon radical having from 1 to 14 carbon atoms. R^a is then in particular as defined for R^{aa} in the NZ-C group.

30

Among the compounds of the formula I where NZ is a group of formula NZ-D, preference is given in particular to the compounds of the formula I-Ab and the tautomers I-Ab' defined below:



- 5 In the formulae I-Ab and I-Ab', A, B, D, J', Y', R, R^c, R^e and n are each as defined above and in particular as defined above with preference.

The variable n is 0, 1, 2 or 3, in particular 0 or 1 and especially 0. R^d are each independently C₁-C₄-alkyl, C₁-C₄-hydroxyalkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, CN, OR¹, NR²R³,
 10 NO₂, SR⁴, SO₂R⁴, SO₂NR²R³, CONR²R³, COOR⁵, COR⁶, C₁-C₂-fluoroalkyl, C₁-C₂-fluoroalkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₂-C₆-alkenyloxy, C₂-C₆-alkynyloxy, C₃-C₆-cycloalkyl, C₃-C₆-cycloalkyl or halogen, and is in particular selected from C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₂-fluoroalkyl and halogen.


- 15 In particular, J' in the formulae I-Ab and I-Ab' is CH₂. Y' is in particular CH₂.

Among the compounds I-Ab and I-Ab', particular preference is given to those where D is a (CH₂)_k group or a C(O)(CH₂)_l group, where k and l are each as defined above, where k is in particular 4, 5 or 6 and l is in particular 3, 4 or 5.

- 20 Among the compounds I-Ab and I-Ab', particular preference is given to those where A is N-C(O), in which the carbon atom is bonded to the variable B.

- 25 Among the compounds I-Ab and I-Ab', particular preference is given to those where B is CH₂.

Among the compounds of the formula I where NZ is a group of the formula NZ-D, preference is also given to the compounds of the formula I-Bb defined below and its tautomers:



In formula I-Bb, n, D, J', Y', R^c, R^e, R^{x1} and R^{y1} are each as defined above and in particular as defined above with preference.

5

The variable n is 0, 1, 2 or 3, in particular 0 or 1 and especially 0. R^d are each independently C₁-C₄-alkyl, C₁-C₄-hydroxyalkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, CN, OR¹, NR²R³, NO₂, SR⁴, SO₂R⁴, SO₂NR²R³, CONR²R³, COOR⁵, COR⁶, C₁-C₂-fluoroalkyl, C₁-C₂-fluoroalkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₂-C₆-alkenyloxy, C₂-C₆-alkynyloxy, C₃-C₆-cycloalkyl, C₃-C₆-cycloalkyl or halogen, and is in particular selected from C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₂-fluoroalkyl and halogen.

10

In particular, J' in formula I-Bb is CH₂. Y' is in particular CH₂.

15

Among the compounds I-Bb, particular preference is given to those where D is a (CH₂)_k group or a C(O)(CH₂)_l group, where k and l are each as defined above, where k is in particular 4, 5 or 6 and l is in particular 3, 4 or 5.

20

In substituents OR¹, OR¹¹ and OR²¹, R¹, R¹¹ and R²¹ are frequently H, C₁-C₄-alkyl, CF₃, CHF₂ or phenyl. Especially preferably, OR¹, OR¹¹ and OR²¹ are each methoxy, trifluoromethoxy or phenoxy.

25

In substituents CONR²R³ (and analogously in CONR¹²R¹³ and CONR²²R²³), R² is preferably H or C₁-C₄-alkyl, and R³ is preferably H, C₁-C₄-alkyl or COR⁷. Especially preferably, CONR²R³, CONR¹²R¹³ and CONR²²R²³ are each CONH₂, CONHCH₃, CON(CH₃)₂ or CONHCOCH₃.

30

In substituents NR²R³ (and analogously in NR¹²R¹³ and NR²²R²³), R² is preferably H, C₁-C₄-alkyl or phenyl-substituted C₁-C₄-alkyl, and R³ is H, C₁-C₄-alkyl or COR⁷. Especially preferably, NR²R³, NR¹²R¹³ and NR²²R²³ are each NH₂, NHCH₃, N(CH₃)₂, NH-benzyl or NHCOCH₃.

35

In substituents SO₂NR²R³ (and analogously in SO₂NR¹²R¹³ and SO₂NR²²R²³), R² is preferably H or C₁-C₄-alkyl, and R³ is preferably H, C₁-C₄-alkyl or COR⁷. Especially preferably, SO₂NR²R³, SO₂NR¹²R¹³ and SO₂NR²²R²³ are each sulfamoyl.

24

When R^2 , R^3 in the substituents NR^2R^3 , $CONR^2R^3$, $SO_2NR^2R^3$ (analogously in $CONR^{12}R^{13}$, $CONR^{22}R^{23}$, $NR^{12}R^{13}$, $NR^{22}R^{23}$, $SO_2NR^{12}R^{13}$ and $SO_2NR^{22}R^{23}$), together with the nitrogen atom to which they are bonded, are a 5- or 6-membered, saturated or unsaturated N-heterocycle, the NR^2R^3 , $NR^{12}R^{13}$ and $NR^{22}R^{23}$ groups in these radicals
 5 are, for example, N-pyrrolidinyl, N-piperidinyl, morpholin-1-yl or 4-methylpiperazin-1-yl.

In substituents SR^4 , SR^{14} and SR^{24} , R^4 , R^{14} and R^{24} are preferably each C_1 - C_4 -alkyl. Especially preferably, SR^4 is thiomethyl.

10 In substituents SO_2R^4 , SO_2R^{14} and SO_2R^{24} , R^4 , R^{14} and R^{24} are preferably each C_1 - C_4 -alkyl, C_1 - C_4 -haloalkyl or phenyl which optionally has a C_1 - C_4 -alkyl group as substituent. Especially preferably, SO_2R^4 , SO_2R^{14} and SO_2R^{24} are each methylsulfonyl.

15 In substituents $COOR^5$, $COOR^{15}$ and $COOR^{25}$, R^5 , R^{15} and R^{25} are frequently H or C_1 - C_4 -alkyl. Especially preferably, $COOR^5$, $COOR^{15}$ and $COOR^{25}$ are each C_1 - C_4 -alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, i-propoxycarbonyl, n-butoxycarbonyl or t-butoxycarbonyl.

20 In substituents COR^6 (analogously in COR^{16} and COR^{26}), R^6 is preferably H, C_1 - C_4 -alkyl or optionally substituted phenyl. Especially preferably, COR^6 , COR^{16} and COR^{26} are each formyl, acetyl or benzoyl.

25 In substituents $O-COR^6$ (analogously in $O-COR^{16}$ and $O-COR^{26}$), R^6 is preferably H, C_1 - C_4 -alkyl or optionally substituted phenyl. Especially preferably, $OCOR^6$, $O-COR^{16}$ and $O-COR^{26}$ are each formyloxy, acetyloxy or benzoyloxy.

30 In substituents COR^7 (analogously in COR^{17} and COR^{27}), R^7 is preferably H, C_1 - C_4 -alkyl or optionally substituted phenyl. Especially preferably, COR^7 , COR^{17} and COR^{27} are each formyl, acetyl or benzoyl.

In the NR^8 group, R^8 is preferably hydrogen or methyl.

In substituents COR^9 , R^9 is preferably H, C_1 - C_4 -alkyl or optionally substituted phenyl. Especially preferably, COR^9 is formyl, acetyl or benzoyl.

35 In the $=N-R^z$ group, R^z is preferably OH, C_1 - C_4 -alkyl or C_1 - C_4 -alkoxy.

40 With regard to the use of the inventive compounds as dopamine D_3 receptor ligands, particular preference is given to the compounds IA and IB and in particular to the compounds IAa and IBa.

25

Very particular preference is given to the compounds of the formula I-Aa.a, where the variables D, E and Ar are each as defined above, in particular as defined above with preference. Examples of such compounds are the compounds I-Aa.a.1 to I-Aa.a.708, in which the variables D, E and Ar together are each as defined in one line of Table A.

5




Table A:

	D	E	R ^a
A-1	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-trifluoromethylpyrimidin-6-yl
A-2	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-difluoromethylpyrimidin-6-yl
A-3	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-phenylpyrimidin-6-yl
A-4	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-methylpyrimidin-6-yl
A-5	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-ethylpyrimidin-6-yl
A-6	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-n-propylpyrimidin-6-yl
A-7	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-isopropylpyrimidin-6-yl
A-8	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2,4-bis(tert-butyl)pyrimidin-6-yl
A-9	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-cyclopropylpyrimidin-6-yl
A-10	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-cyclobutylpyrimidin-6-yl
A-11	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-trifluoromethylpyrimidin-6-yl
A-12	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-difluoromethylpyrimidin-6-yl
A-13	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-phenylpyrimidin-6-yl
A-14	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-methylpyrimidin-6-yl
A-15	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-ethylpyrimidin-6-yl
A-16	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-n-propylpyrimidin-6-yl
A-17	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-isopropylpyrimidin-6-yl
A-18	trans-CH ₂ -CH=CH-CH ₂	-	2,4-bis(tert-butyl)pyrimidin-6-yl
A-19	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-cyclopropylpyrimidin-6-yl
A-20	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-cyclobutylpyrimidin-6-yl
A-21	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-trifluoromethylpyrimidin-6-yl
A-22	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-difluoromethylpyrimidin-6-yl
A-23	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-phenylpyrimidin-6-yl
A-24	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-methylpyrimidin-6-yl
A-25	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-ethylpyrimidin-6-yl
A-26	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-n-propylpyrimidin-6-yl
A-27	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-isopropylpyrimidin-6-yl

	D	E	R ^a
A-28	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2,4-bis(tert-butyl)pyrimidin-6-yl
A-29	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-cyclopropylpyrimidin-6-yl
A-30	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-cyclobutylpyrimidin-6-yl
A-31	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-trifluoromethylpyrimidin-6-yl
A-32	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-difluoromethylpyrimidin-6-yl
A-33	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-phenylpyrimidin-6-yl
A-34	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-methylpyrimidin-6-yl
A-35	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-ethylpyrimidin-6-yl
A-36	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-n-propylpyrimidin-6-yl
A-37	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-isopropylpyrimidin-6-yl
A-38	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2,4-bis(tert-butyl)pyrimidin-6-yl
A-39	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-cyclopropylpyrimidin-6-yl
A-40	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-cyclobutylpyrimidin-6-yl
A-41	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-trifluoromethylpyrimidin-6-yl
A-42	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-difluoromethylpyrimidin-6-yl
A-43	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-phenylpyrimidin-6-yl
A-44	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-methylpyrimidin-6-yl
A-45	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-ethylpyrimidin-6-yl
A-46	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-n-propylpyrimidin-6-yl
A-47	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-isopropylpyrimidin-6-yl
A-48	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2,4-bis(tert-butyl)pyrimidin-6-yl
A-49	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-cyclopropylpyrimidin-6-yl
A-50	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-cyclobutylpyrimidin-6-yl
A-51	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-trifluoromethylpyrimidin-6-yl
A-52	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-difluoromethylpyrimidin-6-yl
A-53	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-phenylpyrimidin-6-yl
A-54	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-methylpyrimidin-6-yl
A-55	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-ethylpyrimidin-6-yl
A-56	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-n-propylpyrimidin-6-yl
A-57	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-isopropylpyrimidin-6-yl
A-58	C(O)-CH ₂ -CH ₂ -CH ₂	-	2,4-bis(tert-butyl)pyrimidin-6-yl
A-59	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-cyclopropylpyrimidin-6-yl
A-60	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-cyclobutylpyrimidin-6-yl
A-61	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-trifluoromethylpyrimidin-6-yl
A-62	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-difluoromethylpyrimidin-6-yl
A-63	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-phenylpyrimidin-6-yl
A-64	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-methylpyrimidin-6-yl
A-65	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-ethylpyrimidin-6-yl
A-66	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-n-propylpyrimidin-6-yl

	D	E	R ^a
A-67	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-isopropylpyrimidin-6-yl
A-68	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2,4-bis(tert-butyl)pyrimidin-6-yl
A-69	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-cyclopropylpyrimidin-6-yl
A-70	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-cyclobutylpyrimidin-6-yl
A-71	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-trifluoromethylpyridin-6-yl
A-72	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-difluoromethylpyridin-6-yl
A-73	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-phenylpyridin-6-yl
A-74	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-methylpyridin-6-yl
A-75	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-ethylpyridin-6-yl
A-76	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-n-propylpyridin-6-yl
A-77	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-isopropylpyridin-6-yl
A-78	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2,4-bis(tert-butyl)pyridin-6-yl
A-79	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-cyclopropylpyridin-6-yl
A-80	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-cyclobutylpyridin-6-yl
A-81	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-trifluoromethylpyridin-6-yl
A-82	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-difluoromethylpyridin-6-yl
A-83	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-phenylpyridin-6-yl
A-84	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-methylpyridin-6-yl
A-85	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-ethylpyridin-6-yl
A-86	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-n-propylpyridin-6-yl
A-87	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-isopropylpyridin-6-yl
A-88	trans-CH ₂ -CH=CH-CH ₂	-	2,4-bis(tert-butyl)pyridin-6-yl
A-89	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-cyclopropylpyridin-6-yl
A-90	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-cyclobutylpyridin-6-yl
A-91	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-trifluoromethylpyridin-6-yl
A-92	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-difluoromethylpyridin-6-yl
A-93	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-phenylpyridin-6-yl
A-94	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-methylpyridin-6-yl
A-95	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-ethylpyridin-6-yl
A-96	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-n-propylpyridin-6-yl
A-97	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-isopropylpyridin-6-yl
A-98	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2,4-bis(tert-butyl)pyridin-6-yl
A-99	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-cyclopropylpyridin-6-yl
A-100	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-cyclobutylpyridin-6-yl
A-101	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-trifluoromethylpyridin-6-yl
A-102	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-difluoromethylpyridin-6-yl
A-103	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-phenylpyridin-6-yl
A-104	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-methylpyridin-6-yl
A-105	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-ethylpyridin-6-yl

	D	E	R ^a
A-106	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-n-propylpyridin-6-yl
A-107	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-isopropylpyridin-6-yl
A-108	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2,4-bis(tert-butyl)pyridin-6-yl
A-109	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-cyclopropylpyridin-6-yl
A-110	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-cyclobutylpyridin-6-yl
A-111	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-trifluoromethylpyridin-6-yl
A-112	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-difluoromethylpyridin-6-yl
A-113	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-phenylpyridin-6-yl
A-114	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-methylpyridin-6-yl
A-115	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-ethylpyridin-6-yl
A-116	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-n-propylpyridin-6-yl
A-117	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-isopropylpyridin-6-yl
A-118	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2,4-bis(tert-butyl)pyridin-6-yl
A-119	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-cyclopropylpyridin-6-yl
A-120	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-cyclobutylpyridin-6-yl
A-121	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-trifluoromethylpyridin-6-yl
A-122	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-difluoromethylpyridin-6-yl
A-123	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-phenylpyridin-6-yl
A-124	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-methylpyridin-6-yl
A-125	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-ethylpyridin-6-yl
A-126	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-n-propylpyridin-6-yl
A-127	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-isopropylpyridin-6-yl
A-128	C(O)-CH ₂ -CH ₂ -CH ₂	-	2,4-bis(tert-butyl)pyridin-6-yl
A-129	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-cyclopropylpyridin-6-yl
A-130	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-cyclobutylpyridin-6-yl
A-131	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-trifluoromethylpyridin-6-yl
A-132	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-difluoromethylpyridin-6-yl
A-133	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-phenylpyridin-6-yl
A-134	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-methylpyridin-6-yl
A-135	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-ethylpyridin-6-yl
A-136	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-n-propylpyridin-6-yl
A-137	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-isopropylpyridin-6-yl
A-138	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2,4-bis(tert-butyl)pyridin-6-yl
A-139	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-cyclopropylpyridin-6-yl
A-140	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-cyclobutylpyridin-6-yl
A-141	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-trifluoromethyltriazin-6-yl
A-142	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-difluoromethyltriazin-6-yl
A-143	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-phenyltriazin-6-yl
A-144	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-methyltriazin-6-yl

	D	E	R ^a
A-145	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-ethyltriazin-6-yl
A-146	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-n-propyltriazin-6-yl
A-147	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-isopropyltriazin-6-yl
A-148	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2,4-bis(tert-butyl)triazin-6-yl
A-149	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-cyclopropyltriazin-6-yl
A-150	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-cyclobutyltriazin-6-yl
A-151	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-trifluoromethyltriazin-6-yl
A-152	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-difluoromethyltriazin-6-yl
A-153	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-phenyltriazin-6-yl
A-154	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-methyltriazin-6-yl
A-155	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-ethyltriazin-6-yl
A-156	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-n-propyltriazin-6-yl
A-157	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-isopropyltriazin-6-yl
A-158	trans-CH ₂ -CH=CH-CH ₂	-	2,4-bis(tert-butyl)triazin-6-yl
A-159	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-cyclopropyltriazin-6-yl
A-160	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-4-cyclobutyltriazin-6-yl
A-161	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-trifluoromethyltriazin-6-yl
A-162	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-difluoromethyltriazin-6-yl
A-163	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-phenyltriazin-6-yl
A-164	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-methyltriazin-6-yl
A-165	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-ethyltriazin-6-yl
A-166	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-n-propyltriazin-6-yl
A-167	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-isopropyltriazin-6-yl
A-168	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2,4-bis(tert-butyl)triazin-6-yl
A-169	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-cyclopropyltriazin-6-yl
A-170	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-4-cyclobutyltriazin-6-yl
A-171	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-trifluoromethyltriazin-6-yl
A-172	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-difluoromethyltriazin-6-yl
A-173	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-phenyltriazin-6-yl
A-174	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-methyltriazin-6-yl
A-175	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-ethyltriazin-6-yl
A-176	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-n-propyltriazin-6-yl
A-177	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-isopropyltriazin-6-yl
A-178	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2,4-bis(tert-butyl)triazin-6-yl
A-179	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-cyclopropyltriazin-6-yl
A-180	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-4-cyclobutyltriazin-6-yl
A-181	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-trifluoromethyltriazin-6-yl
A-182	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-difluoromethyltriazin-6-yl
A-183	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-phenyltriazin-6-yl

	D	E	R ^a
A-184	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-methyltriazin-6-yl
A-185	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-ethyltriazin-6-yl
A-186	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-n-propyltriazin-6-yl
A-187	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-isopropyltriazin-6-yl
A-188	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2,4-bis(tert-butyl)triazin-6-yl
A-189	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-cyclopropyltriazin-6-yl
A-190	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-4-cyclobutyltriazin-6-yl
A-191	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-trifluoromethyltriazin-6-yl
A-192	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-difluoromethyltriazin-6-yl
A-193	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-phenyltriazin-6-yl
A-194	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-methyltriazin-6-yl
A-195	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-ethyltriazin-6-yl
A-196	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-n-propyltriazin-6-yl
A-197	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-isopropyltriazin-6-yl
A-198	C(O)-CH ₂ -CH ₂ -CH ₂	-	2,4-bis(tert-butyl)triazin-6-yl
A-199	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-cyclopropyltriazin-6-yl
A-200	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-cyclobutyltriazin-6-yl
A-201	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-trifluoromethyltriazin-6-yl
A-202	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-difluoromethyltriazin-6-yl
A-203	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-phenyltriazin-6-yl
A-204	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-methyltriazin-6-yl
A-205	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-ethyltriazin-6-yl
A-206	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-n-propyltriazin-6-yl
A-207	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-isopropyltriazin-6-yl
A-208	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2,4-bis(tert-butyl)triazin-6-yl
A-209	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-cyclopropyltriazin-6-yl
A-210	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-4-cyclobutyltriazin-6-yl
A-211	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-trifluoromethylpyridin-6-yl
A-212	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-difluoromethylpyridin-6-yl
A-213	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-phenylpyridin-6-yl
A-214	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-methylpyridin-6-yl
A-215	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-ethylpyridin-6-yl
A-216	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-n-propylpyridin-6-yl
A-217	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-isopropylpyridin-6-yl
A-218	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-cyclopropylpyridin-6-yl
A-219	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-cyclobutylpyridin-6-yl
A-220	trans-CH ₂ -CH=CH-CH ₂	-	4-tert-butyl-2-trifluoromethylpyridin-6-yl
A-221	trans-CH ₂ -CH=CH-CH ₂	-	4-tert-butyl-2-difluoromethylpyridin-6-yl
A-222	trans-CH ₂ -CH=CH-CH ₂	-	4-tert-butyl-2-phenylpyridin-6-yl

	D	E	R ^a
A-223	trans-CH ₂ -CH=CH-CH ₂	-	4-tert-butyl-2-methylpyridin-6-yl
A-224	trans-CH ₂ -CH=CH-CH ₂	-	4-tert-butyl-2-ethylpyridin-6-yl
A-225	trans-CH ₂ -CH=CH-CH ₂	-	4-tert-butyl-2-n-propylpyridin-6-yl
A-226	trans-CH ₂ -CH=CH-CH ₂	-	4-tert-butyl-2-isopropylpyridin-6-yl
A-227	trans-CH ₂ -CH=CH-CH ₂	-	4-tert-butyl-2-cyclopropylpyridin-6-yl
A-228	trans-CH ₂ -CH=CH-CH ₂	-	4-tert-butyl-2-cyclobutylpyridin-6-yl
A-229	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	4-tert-butyl-2-trifluoromethylpyridin-6-yl
A-230	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	4-tert-butyl-2-difluoromethylpyridin-6-yl
A-231	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	4-tert-butyl-2-phenylpyridin-6-yl
A-232	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	4-tert-butyl-2-methylpyridin-6-yl
A-233	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	4-tert-butyl-2-ethylpyridin-6-yl
A-234	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	4-tert-butyl-2-n-propylpyridin-6-yl
A-235	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	4-tert-butyl-2-isopropylpyridin-6-yl
A-236	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	4-tert-butyl-2-cyclopropylpyridin-6-yl
A-237	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	4-tert-butyl-2-cyclobutylpyridin-6-yl
A-238	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	4-tert-butyl-2-trifluoromethylpyridin-6-yl
A-239	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	4-tert-butyl-2-difluoromethylpyridin-6-yl
A-240	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	4-tert-butyl-2-phenylpyridin-6-yl
A-241	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	4-tert-butyl-2-methylpyridin-6-yl
A-242	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	4-tert-butyl-2-ethylpyridin-6-yl
A-243	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	4-tert-butyl-2-n-propylpyridin-6-yl
A-244	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	4-tert-butyl-2-isopropylpyridin-6-yl
A-245	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	4-tert-butyl-2-cyclopropylpyridin-6-yl
A-246	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	4-tert-butyl-2-cyclobutylpyridin-6-yl
A-247	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	4-tert-butyl-2-trifluoromethylpyridin-6-yl
A-248	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	4-tert-butyl-2-difluoromethylpyridin-6-yl
A-249	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	4-tert-butyl-2-phenylpyridin-6-yl
A-250	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	4-tert-butyl-2-methylpyridin-6-yl
A-251	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	4-tert-butyl-2-ethylpyridin-6-yl
A-252	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	4-tert-butyl-2-n-propylpyridin-6-yl
A-253	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	4-tert-butyl-2-isopropylpyridin-6-yl
A-254	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	4-tert-butyl-2-cyclopropylpyridin-6-yl
A-255	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	4-tert-butyl-2-cyclobutylpyridin-6-yl
A-256	C(O)-CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-trifluoromethylpyridin-6-yl
A-257	C(O)-CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-difluoromethylpyridin-6-yl
A-258	C(O)-CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-phenylpyridin-6-yl
A-259	C(O)-CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-methylpyridin-6-yl
A-260	C(O)-CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-ethylpyridin-6-yl
A-261	C(O)-CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-n-propylpyridin-6-yl

	D	E	R ^a
A-262	C(O)-CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-isopropylpyridin-6-yl
A-263	C(O)-CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-cyclopropylpyridin-6-yl
A-264	C(O)-CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-cyclobutylpyridin-6-yl
A-265	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-trifluoromethylpyridin-6-yl
A-266	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-difluoromethylpyridin-6-yl
A-267	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-phenylpyridin-6-yl
A-268	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-methylpyridin-6-yl
A-269	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-ethylpyridin-6-yl
A-270	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-n-propylpyridin-6-yl
A-271	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-isopropylpyridin-6-yl
A-272	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-cyclopropylpyridin-6-yl
A-273	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-tert-butyl-2-cyclobutylpyridin-6-yl
A-274	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-trifluoromethylpyrimidin-4-yl
A-275	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-difluoromethylpyrimidin-4-yl
A-276	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-phenylpyrimidin-4-yl
A-277	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-methylpyrimidin-4-yl
A-278	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-ethylpyrimidin-4-yl
A-279	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-n-propylpyrimidin-4-yl
A-280	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-isopropylpyrimidin-4-yl
A-281	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2,6-bis(tert-butyl)pyrimidin-4-yl
A-282	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-cyclopropylpyrimidin-4-yl
A-283	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-cyclobutylpyrimidin-4-yl
A-284	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-6-trifluoromethylpyrimidin-4-yl
A-285	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-6-difluoromethylpyrimidin-4-yl
A-286	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-6-phenylpyrimidin-4-yl
A-287	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-6-methylpyrimidin-4-yl
A-288	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-6-ethylpyrimidin-4-yl
A-289	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-6-n-propylpyrimidin-4-yl
A-290	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-6-isopropylpyrimidin-4-yl
A-291	trans-CH ₂ -CH=CH-CH ₂	-	2,6-bis(tert-butyl)pyrimidin-4-yl
A-292	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-6-cyclopropylpyrimidin-4-yl
A-293	trans-CH ₂ -CH=CH-CH ₂	-	2-tert-butyl-6-cyclobutylpyrimidin-4-yl
A-294	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-6-trifluoromethylpyrimidin-4-yl
A-295	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-6-difluoromethylpyrimidin-4-yl
A-296	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-6-phenylpyrimidin-4-yl
A-297	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-6-methylpyrimidin-4-yl
A-298	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-6-ethylpyrimidin-4-yl
A-299	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-6-n-propylpyrimidin-4-yl
A-300	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-6-isopropylpyrimidin-4-yl

	D	E	R ^a
A-301	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2,6-bis(tert-butyl)pyrimidin-4-yl
A-302	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-6-cyclopropylpyrimidin-4-yl
A-303	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-tert-butyl-6-cyclobutylpyrimidin-4-yl
A-304	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-6-trifluoromethylpyrimidin-4-yl
A-305	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-6-difluoromethylpyrimidin-4-yl
A-306	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-6-phenylpyrimidin-4-yl
A-307	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-6-methylpyrimidin-4-yl
A-308	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-6-ethylpyrimidin-4-yl
A-309	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-6-n-propylpyrimidin-4-yl
A-310	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-6-isopropylpyrimidin-4-yl
A-311	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2,6-bis(tert-butyl)pyrimidin-4-yl
A-312	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-6-cyclopropylpyrimidin-4-yl
A-313	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-tert-butyl-6-cyclobutylpyrimidin-4-yl
A-314	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-6-trifluoromethylpyrimidin-4-yl
A-315	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-6-difluoromethylpyrimidin-4-yl
A-316	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-6-phenylpyrimidin-4-yl
A-317	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-6-methylpyrimidin-4-yl
A-318	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-6-ethylpyrimidin-4-yl
A-319	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-6-n-propylpyrimidin-4-yl
A-320	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-6-isopropylpyrimidin-4-yl
A-321	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2,6-bis(tert-butyl)pyrimidin-4-yl
A-322	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-6-cyclopropylpyrimidin-4-yl
A-323	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-tert-butyl-6-cyclobutylpyrimidin-4-yl
A-324	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-trifluoromethylpyrimidin-4-yl
A-325	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-difluoromethylpyrimidin-4-yl
A-326	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-phenylpyrimidin-4-yl
A-327	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-methylpyrimidin-4-yl
A-328	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-ethylpyrimidin-4-yl
A-329	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-n-propylpyrimidin-4-yl
A-330	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-isopropylpyrimidin-4-yl
A-331	C(O)-CH ₂ -CH ₂ -CH ₂	-	2,6-bis(tert-butyl)pyrimidin-4-yl
A-332	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-cyclopropylpyrimidin-4-yl
A-333	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-cyclobutylpyrimidin-4-yl
A-334	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-trifluoromethylpyrimidin-4-yl
A-335	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-difluoromethylpyrimidin-4-yl
A-336	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-phenylpyrimidin-4-yl
A-337	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-methylpyrimidin-4-yl
A-338	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-ethylpyrimidin-4-yl
A-339	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-n-propylpyrimidin-4-yl

	D	E	R ^a
A-340	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-isopropylpyrimidin-4-yl
A-341	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2,6-bis(tert-butyl)pyrimidin-4-yl
A-342	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-cyclopropylpyrimidin-4-yl
A-343	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-tert-butyl-6-cyclobutylpyrimidin-4-yl
A-344	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	5-tert-butyl-3-trifluoromethylphenyl
A-345	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	5-tert-butyl-3-difluoromethylphenyl
A-346	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	5-tert-butyl-3-phenylphenyl
A-347	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-tert-butyl-5-methylphenyl
A-348	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-tert-butyl-5-ethylphenyl
A-349	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-tert-butyl-5-n-propylphenyl
A-350	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-tert-butyl-5-isopropylphenyl
A-351	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3,5-bis(tert-butyl)phenyl
A-352	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-tert-butyl-5-cyclopropylphenyl
A-353	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-tert-butyl-5-cyclobutylphenyl
A-354	trans-CH ₂ -CH=CH-CH ₂	-	5-tert-butyl-3-trifluoromethylphenyl
A-355	trans-CH ₂ -CH=CH-CH ₂	-	5-tert-butyl-3-difluoromethylphenyl
A-356	trans-CH ₂ -CH=CH-CH ₂	-	5-tert-butyl-3-phenylphenyl
A-357	trans-CH ₂ -CH=CH-CH ₂	-	3-tert-butyl-5-methylphenyl
A-358	trans-CH ₂ -CH=CH-CH ₂	-	3-tert-butyl-5-ethylphenyl
A-359	trans-CH ₂ -CH=CH-CH ₂	-	3-tert-butyl-5-n-propylphenyl
A-360	trans-CH ₂ -CH=CH-CH ₂	-	3-tert-butyl-5-isopropylphenyl
A-361	trans-CH ₂ -CH=CH-CH ₂	-	3,5-bis(tert-butyl)phenyl
A-362	trans-CH ₂ -CH=CH-CH ₂	-	3-tert-butyl-5-cyclopropylphenyl
A-363	trans-CH ₂ -CH=CH-CH ₂	-	3-tert-butyl-5-cyclobutylphenyl
A-364	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	5-tert-butyl-3-trifluoromethylphenyl
A-365	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	5-tert-butyl-3-difluoromethylphenyl
A-366	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	5-tert-butyl-3-phenylphenyl
A-367	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	3-tert-butyl-5-methylphenyl
A-368	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	3-tert-butyl-5-ethylphenyl
A-369	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	3-tert-butyl-5-n-propylphenyl
A-370	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	3-tert-butyl-5-isopropylphenyl
A-371	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	3,5-bis(tert-butyl)phenyl
A-372	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	3-tert-butyl-5-cyclopropylphenyl
A-373	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	3-tert-butyl-5-cyclobutylphenyl
A-374	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	5-tert-butyl-3-trifluoromethylphenyl
A-375	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	5-tert-butyl-3-difluoromethylphenyl
A-376	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	5-tert-butyl-3-phenylphenyl
A-377	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	3-tert-butyl-5-methylphenyl
A-378	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	3-tert-butyl-5-ethylphenyl

	D	E	R ^a
A-379	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	3-tert-butyl-5-n-propylphenyl
A-380	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	3-tert-butyl-5-isopropylphenyl
A-381	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	3,5-bis(tert-butyl)phenyl
A-382	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	3-tert-butyl-5-cyclopropylphenyl
A-383	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	3-tert-butyl-5-cyclobutylphenyl
A-384	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	5-tert-butyl-3-trifluoromethylphenyl
A-385	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	5-tert-butyl-3-difluoromethylphenyl
A-386	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	5-tert-butyl-3-phenylphenyl
A-387	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	3-tert-butyl-5-methylphenyl
A-388	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	3-tert-butyl-5-ethylphenyl
A-389	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	3-tert-butyl-5-n-propylphenyl
A-390	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	3-tert-butyl-5-isopropylphenyl
A-391	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	3,5-bis(tert-butyl)phenyl
A-392	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	3-tert-butyl-5-cyclopropylphenyl
A-393	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	3-tert-butyl-5-cyclobutylphenyl
A-394	C(O)-CH ₂ -CH ₂ -CH ₂	-	5-tert-butyl-3-trifluoromethylphenyl
A-395	C(O)-CH ₂ -CH ₂ -CH ₂	-	5-tert-butyl-3-difluoromethylphenyl
A-396	C(O)-CH ₂ -CH ₂ -CH ₂	-	5-tert-butyl-3-phenylphenyl
A-397	C(O)-CH ₂ -CH ₂ -CH ₂	-	3-tert-butyl-5-methylphenyl
A-398	C(O)-CH ₂ -CH ₂ -CH ₂	-	3-tert-butyl-5-ethylphenyl
A-399	C(O)-CH ₂ -CH ₂ -CH ₂	-	3-tert-butyl-5-n-propylphenyl
A-400	C(O)-CH ₂ -CH ₂ -CH ₂	-	3-tert-butyl-5-isopropylphenyl
A-401	C(O)-CH ₂ -CH ₂ -CH ₂	-	3,5-bis(tert-butyl)phenyl
A-402	C(O)-CH ₂ -CH ₂ -CH ₂	-	3-tert-butyl-5-cyclopropylphenyl
A-403	C(O)-CH ₂ -CH ₂ -CH ₂	-	3-tert-butyl-5-cyclobutylphenyl
A-404	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	5-tert-butyl-3-trifluoromethylphenyl
A-405	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	5-tert-butyl-3-difluoromethylphenyl
A-406	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	5-tert-butyl-3-phenylphenyl
A-407	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-tert-butyl-5-methylphenyl
A-408	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-tert-butyl-5-ethylphenyl
A-409	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-tert-butyl-5-n-propylphenyl
A-410	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-tert-butyl-5-isopropylphenyl
A-411	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3,5-bis(tert-butyl)phenyl
A-412	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-tert-butyl-5-cyclopropylphenyl
A-413	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-tert-butyl-5-cyclobutylphenyl
A-414			
A-415	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-methylphenyl
A-416	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-fluorophenyl
A-417	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2,3-dimethylphenyl

	D	E	R ^a
A-418	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-methoxyphenyl
A-419	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-chlorophenyl
A-420	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-ethoxyphenyl
A-421	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-trifluoromethylphenyl
A-422	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2,4-dichlorophenyl
A-423	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3,5-dichlorophenyl
A-424	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2,3-dichlorophenyl
A-425	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-chloro-6-methoxyphenyl
A-426	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3,5-dimethylphenyl
A-427	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-cyanophenyl
A-428	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-chloro-3-trifluoromethylphenyl
A-429	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3,5-trifluoromethylphenyl
A-430	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-methylpyridin-6-yl
A-431	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-cyanopyridin-2-yl
A-432	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-cyanopyridin-6-yl
A-433	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-trifluoromethylpyridin-2-yl
A-434	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-trifluoromethylpyridin-6-yl
A-435	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-chloro-5-trifluoromethylpyridin-2-yl
A-436	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3,5-dichloropyridin-4-yl
A-437	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-trifluoropyrimidin-2-yl
A-438	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	5-bromopyrimidin-2-yl
A-439	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	5-fluoropyrimidin-2-yl
A-440	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-cyanopyridazin-3-yl
A-441	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	5-nitrothiadiazol-2-yl
A-442	CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-methylthiadiazol-2-yl
A-443	trans-CH ₂ -CH=CH-CH ₂	-	2-methylphenyl
A-444	trans-CH ₂ -CH=CH-CH ₂	-	2-fluorophenyl
A-445	trans-CH ₂ -CH=CH-CH ₂	-	2,3-dimethylphenyl
A-446	trans-CH ₂ -CH=CH-CH ₂	-	2-methoxyphenyl
A-447	trans-CH ₂ -CH=CH-CH ₂	-	2-chlorophenyl
A-448	trans-CH ₂ -CH=CH-CH ₂	-	2-ethoxyphenyl
A-449	trans-CH ₂ -CH=CH-CH ₂	-	3-trifluoromethylphenyl
A-450	trans-CH ₂ -CH=CH-CH ₂	-	2,4-dichlorophenyl
A-451	trans-CH ₂ -CH=CH-CH ₂	-	3,5-dichlorophenyl
A-452	trans-CH ₂ -CH=CH-CH ₂	-	2,3-dichlorophenyl
A-453	trans-CH ₂ -CH=CH-CH ₂	-	3-chloro-6-methoxyphenyl
A-454	trans-CH ₂ -CH=CH-CH ₂	-	3,5-dimethylphenyl
A-455	trans-CH ₂ -CH=CH-CH ₂	-	2-cyanophenyl
A-456	trans-CH ₂ -CH=CH-CH ₂	-	4-chloro-3-trifluoromethylphenyl

	D	E	R ^a
A-457	trans-CH ₂ -CH=CH-CH ₂	-	3,5-trifluoromethylphenyl
A-458	trans-CH ₂ -CH=CH-CH ₂	-	2-methylpyridin-6-yl
A-459	trans-CH ₂ -CH=CH-CH ₂	-	3-cyanopyridin-2-yl
A-460	trans-CH ₂ -CH=CH-CH ₂	-	3-cyanopyridin-6-yl
A-461	trans-CH ₂ -CH=CH-CH ₂	-	3-trifluoromethylpyridin-2-yl
A-462	trans-CH ₂ -CH=CH-CH ₂	-	3-trifluoromethylpyridin-6-yl
A-463	trans-CH ₂ -CH=CH-CH ₂	-	3-chloro-5-trifluoromethylpyridin-2-yl
A-464	trans-CH ₂ -CH=CH-CH ₂	-	3,5-dichloropyridin-4-yl
A-465	trans-CH ₂ -CH=CH-CH ₂	-	4-trifluoropyrimidin-2-yl
A-466	trans-CH ₂ -CH=CH-CH ₂	-	5-bromopyrimidin-2-yl
A-467	trans-CH ₂ -CH=CH-CH ₂	-	5-fluoropyrimidin-2-yl
A-468	trans-CH ₂ -CH=CH-CH ₂	-	2-cyanopyridazin-3-yl
A-469	trans-CH ₂ -CH=CH-CH ₂	-	5-nitrothiadiazol-2-yl
A-470	trans-CH ₂ -CH=CH-CH ₂	-	4-methylthiadiazol-2-yl
A-471	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-methylphenyl
A-472	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-fluorophenyl
A-473	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2,3-dimethylphenyl
A-474	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-methoxyphenyl
A-475	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-chlorophenyl
A-476	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-ethoxyphenyl
A-477	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	3-trifluoromethylphenyl
A-478	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2,4-dichlorophenyl
A-479	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	3,5-dichlorophenyl
A-480	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2,3-dichlorophenyl
A-481	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	3-chloro-6-methoxyphenyl
A-482	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	3,5-dimethylphenyl
A-483	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-cyanophenyl
A-484	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	4-chloro-3-trifluoromethylphenyl
A-485	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	3,5-trifluoromethylphenyl
A-486	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-methylpyridin-6-yl
A-487	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	3-cyanopyridin-2-yl
A-488	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	3-cyanopyridin-6-yl
A-489	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	3-trifluoromethylpyridin-2-yl
A-490	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	3-trifluoromethylpyridin-6-yl
A-491	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	3-chloro-5-trifluoromethylpyridin-2-yl
A-492	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	3,5-dichloropyridin-4-yl
A-493	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	4-trifluoropyrimidin-2-yl
A-494	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	5-bromopyrimidin-2-yl
A-495	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	5-fluoropyrimidin-2-yl

	D	E	R ^a
A-496	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	2-cyanopyridazin-3-yl
A-497	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	5-nitrothiadiazol-2-yl
A-498	trans-CH ₂ -C(CH ₃)=CH-CH ₂	-	4-methylthiadiazol-2-yl
A-499	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-methylphenyl
A-500	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-fluorophenyl
A-501	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2,3-dimethylphenyl
A-502	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-methoxyphenyl
A-503	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-chlorophenyl
A-504	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-ethoxyphenyl
A-505	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	3-trifluoromethylphenyl
A-506	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2,4-dichlorophenyl
A-507	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	3,5-dichlorophenyl
A-508	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2,3-dichlorophenyl
A-509	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	3-chloro-6-methoxyphenyl
A-510	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	3,5-dimethylphenyl
A-511	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-cyanophenyl
A-512	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	4-chloro-3-trifluoromethylphenyl
A-513	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	3,5-trifluoromethylphenyl
A-514	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-methylpyridin-6-yl
A-515	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	3-cyanopyridin-2-yl
A-516	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	3-cyanopyridin-6-yl
A-517	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	3-trifluoromethylpyridin-2-yl
A-518	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	3-trifluoromethylpyridin-6-yl
A-519	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	3-chloro-5-trifluoromethylpyridin-2-yl
A-520	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	3,5-dichloropyridin-4-yl
A-521	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	4-trifluoropyrimidin-2-yl
A-522	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	5-bromopyrimidin-2-yl
A-523	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	5-fluoropyrimidin-2-yl
A-524	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	2-cyanopyridazin-3-yl
A-525	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	5-nitrothiadiazol-2-yl
A-526	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	-	4-methylthiadiazol-2-yl
A-527	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-methylphenyl
A-528	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-fluorophenyl
A-529	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2,3-dimethylphenyl
A-530	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-methoxyphenyl
A-531	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-chlorophenyl
A-532	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-ethoxyphenyl
A-533	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	3-trifluoromethylphenyl
A-534	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2,4-dichlorophenyl

	D	E	R ^a
A-535	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	3,5-dichlorophenyl
A-536	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2,3-dichlorophenyl
A-537	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	3-chloro-6-methoxyphenyl
A-538	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	3,5-dimethylphenyl
A-539	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-cyanophenyl
A-540	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	4-chloro-3-trifluoromethylphenyl
A-541	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	3,5-trifluoromethylphenyl
A-542	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-methylpyridin-6-yl
A-543	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	3-cyanopyridin-2-yl
A-544	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	3-cyanopyridin-6-yl
A-545	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	3-trifluoromethylpyridin-2-yl
A-546	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	3-trifluoromethylpyridin-6-yl
A-547	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	3-chloro-5-trifluoromethylpyridin-2-yl
A-548	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	3,5-dichloropyridin-4-yl
A-549	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	4-trifluoropyrimidin-2-yl
A-550	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	5-bromopyrimidin-2-yl
A-551	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	5-fluoropyrimidin-2-yl
A-552	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	2-cyanopyridazin-3-yl
A-553	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	5-nitrothiadiazol-2-yl
A-554	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	-	4-methylthiadiazol-2-yl
A-555	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-methylphenyl
A-556	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-fluorophenyl
A-557	C(O)-CH ₂ -CH ₂ -CH ₂	-	2,3-dimethylphenyl
A-558	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-methoxyphenyl
A-559	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-chlorophenyl
A-560	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-ethoxyphenyl
A-561	C(O)-CH ₂ -CH ₂ -CH ₂	-	3-trifluoromethylphenyl
A-562	C(O)-CH ₂ -CH ₂ -CH ₂	-	2,4-dichlorophenyl
A-563	C(O)-CH ₂ -CH ₂ -CH ₂	-	3,5-dichlorophenyl
A-564	C(O)-CH ₂ -CH ₂ -CH ₂	-	2,3-dichlorophenyl
A-565	C(O)-CH ₂ -CH ₂ -CH ₂	-	3-chloro-6-methoxyphenyl
A-566	C(O)-CH ₂ -CH ₂ -CH ₂	-	3,5-dimethylphenyl
A-567	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-cyanophenyl
A-568	C(O)-CH ₂ -CH ₂ -CH ₂	-	4-chloro-3-trifluoromethylphenyl
A-569	C(O)-CH ₂ -CH ₂ -CH ₂	-	3,5-trifluoromethylphenyl
A-570	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-methylpyridin-6-yl
A-571	C(O)-CH ₂ -CH ₂ -CH ₂	-	3-cyanopyridin-2-yl
A-572	C(O)-CH ₂ -CH ₂ -CH ₂	-	3-cyanopyridin-6-yl
A-573	C(O)-CH ₂ -CH ₂ -CH ₂	-	3-trifluoromethylpyridin-2-yl

	D	E	R ^a
A-574	C(O)-CH ₂ -CH ₂ -CH ₂	-	3-trifluoromethylpyridin-6-yl
A-575	C(O)-CH ₂ -CH ₂ -CH ₂	-	3-chloro-5-trifluoromethylpyridin-2-yl
A-576	C(O)-CH ₂ -CH ₂ -CH ₂	-	3,5-dichloropyridin-4-yl
A-577	C(O)-CH ₂ -CH ₂ -CH ₂	-	4-trifluoropyrimidin-2-yl
A-578	C(O)-CH ₂ -CH ₂ -CH ₂	-	5-bromopyrimidin-2-yl
A-579	C(O)-CH ₂ -CH ₂ -CH ₂	-	5-fluoropyrimidin-2-yl
A-580	C(O)-CH ₂ -CH ₂ -CH ₂	-	2-cyanopyridazin-3-yl
A-581	C(O)-CH ₂ -CH ₂ -CH ₂	-	5-nitrothiadiazol-2-yl
A-582	C(O)-CH ₂ -CH ₂ -CH ₂	-	4-methylthiadiazol-2-yl
A-583	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-methylphenyl
A-584	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-fluorophenyl
A-585	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2,3-dimethylphenyl
A-586	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-methoxyphenyl
A-587	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-chlorophenyl
A-588	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-ethoxyphenyl
A-589	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-trifluoromethylphenyl
A-590	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2,4-dichlorophenyl
A-591	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3,5-dichlorophenyl
A-592	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2,3-dichlorophenyl
A-593	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-chloro-6-methoxyphenyl
A-594	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3,5-dimethylphenyl
A-595	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-cyanophenyl
A-596	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-chloro-3-trifluoromethylphenyl
A-597	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3,5-trifluoromethylphenyl
A-598	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-methylpyridin-6-yl
A-599	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-cyanopyridin-2-yl
A-600	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-cyanopyridin-6-yl
A-601	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-trifluoromethylpyridin-2-yl
A-602	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-trifluoromethylpyridin-6-yl
A-603	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3-chloro-5-trifluoromethylpyridin-2-yl
A-604	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	3,5-dichloropyridin-4-yl
A-605	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-trifluoropyrimidin-2-yl
A-606	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	5-bromopyrimidin-2-yl
A-607	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	5-fluoropyrimidin-2-yl
A-608	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	2-cyanopyridazin-3-yl
A-609	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	5-nitrothiadiazol-2-yl
A-610	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	-	4-methylthiadiazol-2-yl
A-611	CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	3,4-methylphenyl
A-612	CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	3-piperonyl

	D	E	R ^a
A-613	CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	2,5-bis(methoxy)phenyl
A-614	CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	3,5-dichlorophenyl
A-615	CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	3-cyanophenyl
A-616	CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	4-cyanophenyl
A-617	CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	2-pyridyl
A-618	CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	3-pyridyl
A-619	CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	4-pyridyl
A-620	CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	2,3-dichlorophenyl
A-621	CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	2,5-dimethylphenyl
A-622	CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	2-methylnaphthalen-1-yl
A-623	CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	2-thienyl
A-624	CH ₂ -CH ₂ -CH ₂ -CH ₂	CCH ₃	phenyl
A-625	trans-CH ₂ -CH=CH-CH ₂	CH ₂	3,4-methylphenyl
A-626	trans-CH ₂ -CH=CH-CH ₂	CH ₂	3-piperonyl
A-627	trans-CH ₂ -CH=CH-CH ₂	CH ₂	2,5-bis(methoxy)phenyl
A-628	trans-CH ₂ -CH=CH-CH ₂	CH ₂	3,5-dichlorophenyl
A-629	trans-CH ₂ -CH=CH-CH ₂	CH ₂	3-cyanophenyl
A-630	trans-CH ₂ -CH=CH-CH ₂	CH ₂	4-cyanophenyl
A-631	trans-CH ₂ -CH=CH-CH ₂	CH ₂	2-pyridyl
A-632	trans-CH ₂ -CH=CH-CH ₂	CH ₂	3-pyridyl
A-633	trans-CH ₂ -CH=CH-CH ₂	CH ₂	4-pyridyl
A-634	trans-CH ₂ -CH=CH-CH ₂	CH ₂	2,3-dichlorophenyl
A-635	trans-CH ₂ -CH=CH-CH ₂	CH ₂	2,5-dimethylphenyl
A-636	trans-CH ₂ -CH=CH-CH ₂	CH ₂	2-methylnaphthalen-1-yl
A-637	trans-CH ₂ -CH=CH-CH ₂	CH ₂	2-thienyl
A-638	trans-CH ₂ -CH=CH-CH ₂	CCH ₃	phenyl
A-639	trans-CH ₂ -C(CH ₃)=CH-CH ₂	CH ₂	3,4-methylphenyl
A-640	trans-CH ₂ -C(CH ₃)=CH-CH ₂	CH ₂	3-piperonyl
A-641	trans-CH ₂ -C(CH ₃)=CH-CH ₂	CH ₂	2,5-bis(methoxy)phenyl
A-642	trans-CH ₂ -C(CH ₃)=CH-CH ₂	CH ₂	3,5-dichlorophenyl
A-643	trans-CH ₂ -C(CH ₃)=CH-CH ₂	CH ₂	3-cyanophenyl
A-644	trans-CH ₂ -C(CH ₃)=CH-CH ₂	CH ₂	4-cyanophenyl
A-645	trans-CH ₂ -C(CH ₃)=CH-CH ₂	CH ₂	2-pyridyl
A-646	trans-CH ₂ -C(CH ₃)=CH-CH ₂	CH ₂	3-pyridyl
A-647	trans-CH ₂ -C(CH ₃)=CH-CH ₂	CH ₂	4-pyridyl
A-648	trans-CH ₂ -C(CH ₃)=CH-CH ₂	CH ₂	2,3-dichlorophenyl
A-649	trans-CH ₂ -C(CH ₃)=CH-CH ₂	CH ₂	2,5-dimethylphenyl
A-650	trans-CH ₂ -C(CH ₃)=CH-CH ₂	CH ₂	2-methylnaphthalen-1-yl
A-651	trans-CH ₂ -C(CH ₃)=CH-CH ₂	CH ₂	2-thienyl


42

	D	E	R ^a
A-652	trans-CH ₂ -C(CH ₃)=CH-CH ₂	CCH ₃	phenyl
A-653	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	CH ₂	3,4-methylphenyl
A-654	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	CH ₂	3-piperonyl
A-655	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	CH ₂	2,5-bis(methoxy)phenyl
A-656	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	CH ₂	3,5-dichlorophenyl
A-657	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	CH ₂	3-cyanophenyl
A-658	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	CH ₂	4-cyanophenyl
A-659	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	CH ₂	2-pyridyl
A-660	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	CH ₂	3-pyridyl
A-661	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	CH ₂	4-pyridyl
A-662	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	CH ₂	2,3-dichlorophenyl
A-663	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	CH ₂	2,5-dimethylphenyl
A-664	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	CH ₂	2-methylnaphthalen-1-yl
A-665	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	CH ₂	2-thienyl
A-666	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	CCH ₃	phenyl
A-667	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	CH ₂	3,4-methylphenyl
A-668	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	CH ₂	3-piperonyl
A-669	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	CH ₂	2,5-bis(methoxy)phenyl
A-670	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	CH ₂	3,5-dichlorophenyl
A-671	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	CH ₂	3-cyanophenyl
A-672	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	CH ₂	4-cyanophenyl
A-673	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	CH ₂	2-pyridyl
A-674	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	CH ₂	3-pyridyl
A-675	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	CH ₂	4-pyridyl
A-676	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	CH ₂	2,3-dichlorophenyl
A-677	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	CH ₂	2,5-dimethylphenyl
A-678	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	CH ₂	2-methylnaphthalen-1-yl
A-679	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	CH ₂	2-thienyl
A-680	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	CCH ₃	phenyl
A-681	C(O)-CH ₂ -CH ₂ -CH ₂	CH ₂	3,4-methylphenyl
A-682	C(O)-CH ₂ -CH ₂ -CH ₂	CH ₂	3-piperonyl
A-683	C(O)-CH ₂ -CH ₂ -CH ₂	CH ₂	2,5-bis(methoxy)phenyl
A-684	C(O)-CH ₂ -CH ₂ -CH ₂	CH ₂	3,5-dichlorophenyl
A-685	C(O)-CH ₂ -CH ₂ -CH ₂	CH ₂	3-cyanophenyl
A-686	C(O)-CH ₂ -CH ₂ -CH ₂	CH ₂	4-cyanophenyl
A-687	C(O)-CH ₂ -CH ₂ -CH ₂	CH ₂	2-pyridyl
A-688	C(O)-CH ₂ -CH ₂ -CH ₂	CH ₂	3-pyridyl
A-689	C(O)-CH ₂ -CH ₂ -CH ₂	CH ₂	4-pyridyl
A-690	C(O)-CH ₂ -CH ₂ -CH ₂	CH ₂	2,3-dichlorophenyl

43


	D	E	R ^a
A-691	C(O)-CH ₂ -CH ₂ -CH ₂	CH ₂	2,5-dimethylphenyl
A-692	C(O)-CH ₂ -CH ₂ -CH ₂	CH ₂	2-methylnaphthalen-1-yl
A-693	C(O)-CH ₂ -CH ₂ -CH ₂	CH ₂	2-thienyl
A-694	C(O)-CH ₂ -CH ₂ -CH ₂	CCH ₃	phenyl
A-695	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	3,4-methylphenyl
A-696	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	3-piperonyl
A-697	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	2,5-bis(methoxy)phenyl
A-698	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	3,5-dichlorophenyl
A-699	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	3-cyanophenyl
A-700	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	4-cyanophenyl
A-701	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	2-pyridyl
A-702	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	3-pyridyl
A-703	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	4-pyridyl
A-704	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	2,3-dichlorophenyl
A-705	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	2,5-dimethylphenyl
A-706	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	2-methylnaphthalen-1-yl
A-707	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂	2-thienyl
A-708	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	CCH ₃	phenyl

- Particular preference is further given to the compounds of the formula I-Aa.b where the variables D, E and Ar are each as defined above, in particular as defined above with preference. Examples of such compounds are the compounds I-Aa.b.1 to I-Aa.b.708 in which the variables D, E and Ar together are each as defined in one line of Table A.




- Particular preference is further given to the compounds of the formula I-Ba.a where the variables D, E and Ar are each as defined above, in particular as defined above with preference. Examples of such compounds are the compounds I-Ba.a.1 to I-Ba.a.708, in which the variables D, E and Ar together are each as defined in one line of Table A.

44





- Particular preference is further given to the compounds of the formula I-Aa.c where the variables D, E and Ar are each as defined above, in particular as defined above with preference. Examples of such compounds are the compounds I-Aa.c.1 to I-Aa.c.708, in which the variables D, E and Ar together are each as defined in one line of Table A.



- 10 Preference is further given to the compounds of the formulae I-Aa.d and I-Aa.e where the variables D, E and Ar are each as defined above, in particular as defined above with preference. Examples of such compounds are the compounds I-Aa.d.1 to I-Aa.d.708 and the compounds I-Aa.e.1 to I-Aa.e.708 in which the variables D, E and Ar in each case together are as defined in one line of Table A.

15



- 20 Preference is further given to the compounds of the formulae I-Aa.f, I-Aa.g, I-Aa.h, I-Aa.i, I-Aa.k and I-Ba.b, where the variables D and R^{aa} are each as defined above, in particular as defined above with preference. Examples of such compounds are the compounds I-Aa.f.1 to I-Aa.f.98, I-Aa.g.1 to I-Aa.g.98, I-Aa.h.1 to I-Aa.h.98, I-Aa.i.1 to I-

Aa.i.98, I-Aa.k.1 to I-Aa.k.98 and the compounds I-Ba.b.1 to I-Ba.b.98, in which the variables D and R^{aa} in each case together are as defined in one line of Table B.









Table B:


	D	R ^{aa}
B-1	CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂ -cyclohexyl
B-2	CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂ -CH=CH ₂
B-3	CH ₂ -CH ₂ -CH ₂ -CH ₂	pyrrolidin-1-ylcarbonylmethyl
B-4	CH ₂ -CH ₂ -CH ₂ -CH ₂	acetyl
B-5	CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂ CH ₂ -cyclohexyl
B-6	CH ₂ -CH ₂ -CH ₂ -CH ₂	cyclopentyl
B-7	CH ₂ -CH ₂ -CH ₂ -CH ₂	cyclohexyl
B-8	CH ₂ -CH ₂ -CH ₂ -CH ₂	piperazin-1-ylcarbonylmethyl
B-9	CH ₂ -CH ₂ -CH ₂ -CH ₂	cyclopropylcarbonyl
B-10	CH ₂ -CH ₂ -CH ₂ -CH ₂	oxolan-2-ylcarbonyl
B-11	CH ₂ -CH ₂ -CH ₂ -CH ₂	oxolan-2-ylmethyl
B-12	CH ₂ -CH ₂ -CH ₂ -CH ₂	methyl
B-13	CH ₂ -CH ₂ -CH ₂ -CH ₂	ethyl
B-14	CH ₂ -CH ₂ -CH ₂ -CH ₂	n-propyl
B-15	trans-CH ₂ -CH=CH-CH ₂	CH ₂ -cyclohexyl
B-16	trans-CH ₂ -CH=CH-CH ₂	CH ₂ -CH=CH ₂
B-17	trans-CH ₂ -CH=CH-CH ₂	pyrrolidin-1-ylcarbonylmethyl
B-18	trans-CH ₂ -CH=CH-CH ₂	acetyl
B-19	trans-CH ₂ -CH=CH-CH ₂	CH ₂ CH ₂ -cyclohexyl
B-20	trans-CH ₂ -CH=CH-CH ₂	cyclopentyl
B-21	trans-CH ₂ -CH=CH-CH ₂	cyclohexyl
B-22	trans-CH ₂ -CH=CH-CH ₂	piperazin-1-ylcarbonylmethyl
B-23	trans-CH ₂ -CH=CH-CH ₂	cyclopropylcarbonyl
B-24	trans-CH ₂ -CH=CH-CH ₂	oxolan-2-ylcarbonyl
B-25	trans-CH ₂ -CH=CH-CH ₂	oxolan-2-ylmethyl
B-26	trans-CH ₂ -CH=CH-CH ₂	methyl
B-27	trans-CH ₂ -CH=CH-CH ₂	ethyl
B-28	trans-CH ₂ -CH=CH-CH ₂	n-propyl
B-29	trans-CH ₂ -C(CH ₃)=CH-CH ₂	CH ₂ -cyclohexyl
B-30	trans-CH ₂ -C(CH ₃)=CH-CH ₂	CH ₂ -CH=CH ₂
B-31	trans-CH ₂ -C(CH ₃)=CH-CH ₂	pyrrolidin-1-ylcarbonylmethyl
B-32	trans-CH ₂ -C(CH ₃)=CH-CH ₂	acetyl
B-33	trans-CH ₂ -C(CH ₃)=CH-CH ₂	CH ₂ CH ₂ -cyclohexyl
B-34	trans-CH ₂ -C(CH ₃)=CH-CH ₂	cyclopentyl
B-35	trans-CH ₂ -C(CH ₃)=CH-CH ₂	cyclohexyl
B-36	trans-CH ₂ -C(CH ₃)=CH-CH ₂	piperazin-1-ylcarbonylmethyl
B-37	trans-CH ₂ -C(CH ₃)=CH-CH ₂	cyclopropylcarbonyl
B-38	trans-CH ₂ -C(CH ₃)=CH-CH ₂	oxolan-2-ylcarbonyl
B-39	trans-CH ₂ -C(CH ₃)=CH-CH ₂	oxolan-2-ylmethyl

	D	R ^{aa}
B-40	trans-CH ₂ -C(CH ₃)=CH-CH ₂	methyl
B-41	trans-CH ₂ -C(CH ₃)=CH-CH ₂	ethyl
B-42	trans-CH ₂ -C(CH ₃)=CH-CH ₂	n-propyl
B-43	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	CH ₂ -cyclohexyl
B-44	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	CH ₂ -CH=CH ₂
B-45	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	pyrrolidin-1-ylcarbonylmethyl
B-46	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	acetyl
B-47	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	CH ₂ CH ₂ -cyclohexyl
B-48	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	cyclopentyl
B-49	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	cyclohexyl
B-50	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	piperazin-1-ylcarbonylmethyl
B-51	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	cyclopropylcarbonyl
B-52	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	oxolan-2-ylcarbonyl
B-53	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	oxolan-2-ylmethyl
B-54	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	methyl
B-55	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	ethyl
B-56	CH ₂ -CH(CH ₃)-CH ₂ -CH ₂	n-propyl
B-57	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	CH ₂ -cyclohexyl
B-58	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	CH ₂ -CH=CH ₂
B-59	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	pyrrolidin-1-ylcarbonylmethyl
B-60	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	acetyl
B-61	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	CH ₂ CH ₂ -cyclohexyl
B-62	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	cyclopentyl
B-63	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	cyclohexyl
B-64	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	piperazin-1-ylcarbonylmethyl
B-65	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	cyclopropylcarbonyl
B-66	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	oxolan-2-ylcarbonyl
B-67	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	oxolan-2-ylmethyl
B-68	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	methyl
B-69	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	ethyl
B-70	CH ₂ -CH ₂ -CH ₂ -CH(CH ₃)	n-propyl
B-71	C(O)-CH ₂ -CH ₂ -CH ₂	CH ₂ -cyclohexyl
B-72	C(O)-CH ₂ -CH ₂ -CH ₂	CH ₂ -CH=CH ₂
B-73	C(O)-CH ₂ -CH ₂ -CH ₂	pyrrolidin-1-ylcarbonylmethyl
B-74	C(O)-CH ₂ -CH ₂ -CH ₂	acetyl
B-75	C(O)-CH ₂ -CH ₂ -CH ₂	CH ₂ CH ₂ -cyclohexyl
B-76	C(O)-CH ₂ -CH ₂ -CH ₂	cyclopentyl
B-77	C(O)-CH ₂ -CH ₂ -CH ₂	cyclohexyl
B-78	C(O)-CH ₂ -CH ₂ -CH ₂	piperazin-1-ylcarbonylmethyl

	D	R ^{aa}
B-79	C(O)-CH ₂ -CH ₂ -CH ₂	cyclopropylcarbonyl
B-80	C(O)-CH ₂ -CH ₂ -CH ₂	oxolan-2-ylcarbonyl
B-81	C(O)-CH ₂ -CH ₂ -CH ₂	oxolan-2-ylmethyl
B-82	C(O)-CH ₂ -CH ₂ -CH ₂	methyl
B-83	C(O)-CH ₂ -CH ₂ -CH ₂	ethyl
B-84	C(O)-CH ₂ -CH ₂ -CH ₂	n-propyl
B-85	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂ -cyclohexyl
B-86	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂ -CH=CH ₂
B-87	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	pyrrolidin-1-ylcarbonylmethyl
B-88	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	acetyl
B-89	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	CH ₂ CH ₂ -cyclohexyl
B-90	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	cyclopentyl
B-91	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	cyclohexyl
B-92	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	piperazin-1-ylcarbonylmethyl
B-93	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	cyclopropylcarbonyl
B-94	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	oxolan-2-ylcarbonyl
B-95	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	oxolan-2-ylmethyl
B-96	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	methyl
B-97	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	ethyl
B-98	C(O)-CH ₂ -CH ₂ -CH ₂ -CH ₂	n-propyl

The inventive compounds I can be prepared in analogy to the prior art cited at the outset and by known processes for preparing keto lactams. An important route to the inventive compounds is shown in scheme 1.

Scheme 1:




In scheme 1, A, B, D, R^x, R^y and NZ are each as defined above. L₁ and L₂ are each nucleophilically displaceable leaving groups. Examples of suitable nucleophilically displaceable leaving groups are halogen, in particular chlorine, bromine or iodine, alkyl- and arylsulfonate such as mesylate, tosylate. L₁ and L₂ are preferably different from one another and have different reactivity. For example, L₁ is bromine or iodine and L₂ is

chlorine. The reaction conditions required for the reaction correspond to the reaction conditions customary for nucleophilic substitutions. When D is a C(O)alkylene group, L₁ is in particular halogen and especially chlorine.

- 5 Compounds of the general formula IV are either known from the literature, for example from WO 96/02519, WO 97/25324, WO 99/02503, WO 00/42036, DE 10304870.7 or the literature cited in these documents, or can be prepared by the processes described there.
- 10 The compounds of the formula II are likewise known and some are commercially available or can be prepared in analogy to known processes, as described, for example, in: J. Am. Chem. Soc. 1958, 80, p. 2172-2178; J. Chem. Soc. 1959, p. 3111; J. Chem. Soc. 1934, p. 1326; Heterocycles 1977, 8, p. 345-350; Tetrahedron Lett. 1993, 34, 5855; Arch. Pharm. 1991, 324, 579; J. Med. Chem. 1990, 33, 633; J. Med. Chem.
- 15 2000, 43, 1878; J. Org. Chem. 1972, 37, p. 2849, Monatsh. Chem. 1965, 96, 418, Synlett 2002, 8, p. 1350, Tetrahedron Lett, 1993, 34, p. 5855 and J. Photochem. 28 (1985) p. 69-70.

- Some of the inventive compounds can also be prepared by the synthesis shown in
- 20 scheme 2:

Scheme 2:



- 25 In scheme 2, A, B, R^x, R^y and NZ are each as defined above. D is C₂-C₃-alkylene or a CO-C₂-C₁₀-alkylene group where CO is bonded to L₁. L₁ is a nucleophilically displaceable leaving group. For example, L₁ is chlorine, bromine or iodine when D is alkylene. The reaction conditions required for the reaction correspond to the reaction conditions customary for nucleophilic substitutions. When D is a C(O)alkylene group, L₁ is in particular
- 30 halogen and especially chlorine.

- Compounds of the general formula V are likewise known from the literature, for example from WO 96/02519, WO 97/25324, WO 99/02503, WO 00/42036, DE 10304870.7, or from the literature cited in these documents, or can be prepared by the processes
- 35 described there, for example by reacting a compound of the formula IV shown in scheme 1 with a compound L₁-D-L₂ where L and D are each as defined in scheme 1.

Compounds of the formula I where $\text{—}\overset{\text{I}}{\text{A}}\text{—}$ is $\text{—}\overset{\text{I}}{\text{N}}\text{—CH}_2\text{—}$ may also be prepared by re-

ducing compounds of the formula I where $\text{—}\overset{\text{I}}{\text{A}}\text{—}$ is $\text{—}\overset{\text{I}}{\text{N}}\text{—C(=O)—}$. Suitable reducing agents include, for example, aluminum hydrides such as lithium aluminum hydride. Suitable methods for this purpose are known from the prior art, for example from

5 J. Org. Chem. 1972, 37, p. 2849 and can be used analogously for this reaction.

The tautomers I' can be prepared analogously to the preparation of the compound I described here. For example, the tautomers I' can be prepared by the synthesis route shown in scheme 1. The compounds I' where R is alkoxy or an OC(O)R⁹ group can
10 also be prepared from the compounds I by reacting with a suitable alkylating agent or a suitable acylating agent of the formula X'-C(O)R⁹ where X' is halogen and in particular chlorine, optionally in the presence of an auxiliary base, for example by the methods described in Chem. Commun. 1998, p. 2621 or J. Org. Chem. 1959, 24, p. 41-43. The compound I can also be converted to its tautomers I' where R = halogen by treating
15 them with a suitable halogenating agent such as PCl₃ or POCl₃.

Unless stated otherwise, the above-described reactions are generally effected in a solvent at temperatures between room temperature and the boiling point of the solvent used. Usable solvents are, for example, ethers such as diethyl ether, diisopropyl ether,
20 methyl tert-butyl ether or tetrahydrofuran, dimethylformamide, dimethyl sulfoxide, dimethoxyethane, toluene, xylene, acetonitrile, ketones such as acetone or methyl ethyl ketone, or alcohols such as methanol, ethanol or butanol.

If desired, it is possible to work in the presence of a base for neutralization of protons released in the reactions. Suitable bases include inorganic bases such as sodium carbonate or potassium carbonate, sodium hydrogencarbonate or potassium hydrogen-
25 carbonate, and also alkoxides such as sodium methoxide, sodium ethoxide, alkali metal hydrides such as sodium hydride, organometallic compounds such as butyllithium or alkylmagnesium compounds, or organic nitrogen bases such as triethylamine or pyridine. The latter can simultaneously also serve as solvents.
30

The crude product is isolated in a customary manner, for example by filtration, distilling off the solvent or extraction from the reaction mixture, etc. The resulting compounds can be purified in a customary manner, for example by recrystallization from a solvent,
35 chromatography or by conversion to an acid addition salt.

The acid addition salts are typically prepared by mixing the free base with the corresponding acid, optionally in a solution in an organic solvent, for example a low molecular weight alcohol such as methanol, ethanol or propanol, an ether such as methyl tert-

butyl ether, diisopropyl ether, a ketone such as acetone or methyl ethyl ketone, or an ester such as ethyl acetate.

5 The inventive compounds of the formula I are generally highly selective dopamine D₃ receptor ligands which, because of their low affinity for other receptors such as D₁ receptors, D₄ receptors, α 1- and/or α 2-adrenergic receptors, muscarinergic receptors, histaminic receptors, opiate receptors and, in particular, for dopamine D₂ receptors, have fewer side effects than classical neuroleptics which comprise D₂ receptor antagonists.

10 The high affinity of the inventive compounds for D₃ receptors is reflected in very low in vitro K_i values of ordinarily less than 100 nM (nmol/l) and especially of less than 50 nM. Binding affinities for D₃ receptors can, for example, be determined via the displacement of [¹²⁵I]-iodosulpride in receptor-binding studies.

15 Of particular significance in accordance with the invention are compounds whose K_i(D₂)/K_i(D₃) selectivity is preferably at least 10, even better at least 30 and particularly advantageously at least 50. Receptor-binding studies on D₁, D₂ and D₄ receptors can be carried out for example via the displacement of [³H]SCH23390, [¹²⁵I]iodosulpride and [¹²⁵I]spiperone.

20 The compounds can, because of their binding profile, be used for the treatment of conditions which respond to dopamine D₃ ligands, i.e. they are effective for the treatment of those disorders or conditions where an influencing (modulation) of dopamine D₃ receptors leads to an improvement in the clinical condition or to cure of the disease. Examples of such conditions are disorders or conditions of the central nervous system.

30 Disorders or conditions of the central nervous system mean disorders affecting the spinal cord and, in particular, the brain. The term "disorder" in the inventive sense refers to abnormalities which are usually regarded as pathological states or functions and may reveal themselves in the form of particular signs, symptoms and/or dysfunctions. The inventive treatment may be directed at individual disorders, i.e. abnormalities or pathological states, but it is also possible for a plurality of abnormalities, which are causally connected together where appropriate, to be combined into patterns, i.e. syndromes, which can be treated in accordance with the invention.

40 The disorders which can be treated in accordance with the invention include in particular psychiatric and neurological disorders. These comprise in particular organic disorders, symptomatic disorders included, such as psychoses of the acute exogenous reaction type or associated psychoses with an organic or exogenous cause, e.g. associated with metabolic disorders, infections and endocrinopathies; endogenous psycho-

ses such as schizophrenia and schizotypal and delusional disorders; affective disorders such as depressions, mania and manic/depressive states; and combined forms of the disorders described above; neurotic and somatoform disorders, and disorders associated with stress; dissociative disorders, e.g. deficits, clouding and splitting of consciousness and personality disorders; disorders of attention and waking/sleeping behavior, such as behavioral disorders and emotional disorders starting in childhood and adolescence, e.g. hyperactivity in children, intellectual deficits, especially attention deficit disorders, disorders of memory and cognition, e.g. learning and memory impairment (impaired cognitive function), dementia, narcolepsy and sleeping disorders, e.g. restless legs syndrome; developmental disorders; anxiety states; delirium; disorders of the sex life, e.g. male impotence; eating disorders, e.g. anorexia or bulimia; addiction; and other undefined psychiatric disorders.

The disorders which can be treated in accordance with the invention also include parkinsonism and epilepsy and, in particular, the affective disorders associated therewith. Addictive disorders include the psychological disorders and behavioral disorders caused by the abuse of psychotropic substances such as pharmaceuticals or drugs, and other addictive disorders such as, for example, compulsive gambling and impulse control disorders not elsewhere classified. Examples of addictive substances are: opioids (e.g. morphine, heroin, codeine); cocaine; nicotine; alcohol; substances which interact with the GABA chloride channel complex, sedatives, hypnotics or tranquilizers, for example benzodiazepines; LSD; cannabinoids; psychomotor stimulants such as 3,4-methylenedioxy-N-methylamphetamine (Ecstasy); amphetamine and amphetamine-like substances such as methylphenidate or other stimulants, including caffeine. Addictive substances requiring particular attention are opioids, cocaine, amphetamine or amphetamine-like substances, nicotine and alcohol.

With regard to the treatment of addictive disorders, the inventive compounds of the formula I which are particularly preferred are those which themselves have no psychotropic effect. This can also be observed in a test on rats which reduce the self-administration of psychotropic substances, for example cocaine, after administration of compounds which can be used in accordance with the invention.

According to a further aspect of the present invention, the inventive compounds are suitable for the treatment of disorders whose causes can at least in part be attributed to an abnormal activity of dopamine D₃ receptors.

According to another aspect of the present invention, the treatment is directed in particular at those disorders which can be influenced by a binding of, preferably exogenously added, binding partners (ligands) to dopamine D₃ receptors in the sense of an appropriate medical treatment.

The conditions which can be treated with the inventive compounds are frequently characterized by a progressive development, i.e. the states described above change over the course of time, the severity usually increasing and, where appropriate, states possibly interchanging or other states being added to previously existing states.

The inventive compounds can be used to treat a large number of signs, symptoms and/or dysfunctions associated with the disorders of the central nervous system and in particular the aforementioned states. These include for example a distorted relation to reality, lack of insight and the ability to comply with the usual social norms and demands of life, changes in behavior, changes in individual urges such as hunger, sleep, thirst etc. and in mood, disorders of memory and association, personality changes, especially emotional lability, hallucinations, ego disturbances, incoherence of thought, ambivalence, autism, depersonalization or hallucinations, delusional ideas, staccato speech, absence of associated movement, small-step gait, bent posture of trunk and limbs, tremor, mask-like face, monotonous speech, depression, apathy, deficient spontaneity and irresolution, reduced associationability, anxiety, nervous agitation, stammering, social phobia, panic disorders, withdrawal syndromes associated with dependence, expansive syndromes, states of agitation and confusion, dysphoria, dyskinetic syndromes and tic disorders, e.g. Huntington's chorea, Gilles de la Tourette syndrome, vertigo syndromes, e.g. peripheral postural, rotational and vestibular vertigo, melancholia, hysteria, hypochondria and the like. A treatment in the inventive sense includes not only the treatment of acute or chronic signs, symptoms and/or dysfunctions but also a preventive treatment (prophylaxis), in particular as recurrence or episode prophylaxis.

The treatment may be symptomatic, for example directed at suppression of symptoms. It may take place short-term, be directed at the medium term or may also be a long-term treatment, for example as part of maintenance therapy.

The inventive compounds are preferably suitable for the treatment of disorders of the central nervous system, especially for the treatment of affective disorders; neurotic disorders, stress disorders and somatoform disorders and psychoses and specifically for the treatment of schizophrenia and depression. Owing to their high selectivity in relation to the D₃ receptor, the inventive compounds are also for the treatment of renal function disorders, especially of renal function disorders caused by diabetes mellitus (see WO 00/67847).

The inventive use of the described compounds comprises a method within the scope of the treatment. This entails the individual to be treated, preferably a mammal, in particular a human or agricultural or domestic animal, being given an effective amount of one or more compounds, usually formulated in accordance with pharmaceutical and veterinary practice. Whether such a treatment is indicated, and the form it is to take, de-

depends on the individual case and is subject to a medical assessment (diagnosis) which takes account of the signs, symptoms and/or dysfunctions present, the risks of developing certain signs, symptoms and/or dysfunctions, and other factors.

- 5 The treatment usually takes place by administration once or more than once a day, where appropriate together or alternately with other active ingredients or active ingredient-containing products, so that an individual to be treated is given a daily dose preferably of about 0.1 to 1000 mg/kg of body weight on oral administration or of about 0.1 to 100 mg/kg of body weight on parenteral administration.

10

The invention also relates to the production of pharmaceutical compositions for the treatment of an individual, preferably a mammal, in particular a human or agricultural or domestic animal. Thus, the ligands are usually administered in the form of pharmaceutical compositions which comprise a pharmaceutically acceptable excipient with at least one ligand of the invention and, where appropriate, further active ingredients. These compositions can be administered for example by the oral, rectal, transdermal, subcutaneous, intravenous, intramuscular or intranasal route.

15

Examples of suitable pharmaceutical formulations are solid pharmaceutical forms such as oral powders, dusting powders, granules, tablets, especially film-coated tablets, pastilles, sachets, cachets, sugar-coated tablets, capsules such as hard and soft gelatin capsules, suppositories or vaginal pharmaceutical forms, semisolid pharmaceutical forms such as ointments, creams, hydrogels, pastes or patches, and liquid pharmaceutical forms such as solutions, emulsions, especially oil-in-water emulsions, suspensions, for example lotions, preparations for injection and infusion, eye drops and ear drops. Implanted delivery devices can also be used to administer inhibitors of the invention. A further possibility is also to use liposomes or microspheres.

20

25

The compositions are produced by mixing or diluting inhibitors of the invention usually with an excipient. Excipients may be solid, semisolid or liquid materials which serve as vehicle, carrier or medium for the active ingredient.

30

Suitable excipients are listed in the relevant pharmaceutical monographs. The formulations may additionally comprise pharmaceutically acceptable carriers or conventional excipients such as lubricants; wetting agents; emulsifying and suspending agents; preservatives; antioxidants; antiirritants; chelating agents; tablet-coating aids; emulsion stabilizers; film formers; gel formers; odor-masking agents; masking flavors; resins; hydrocolloids; solvents; solubilizers; neutralizers; permeation promoters; pigments; quaternary ammonium compounds; refatting and superfatting agents; ointment, cream or oil bases; silicone derivatives; spreading aids; stabilizers; sterilants; suppository bases; tablet excipients, such as binders, fillers, lubricants, disintegrants or coatings;

35

40

propellants; desiccants; opacifiers; thickeners; waxes; plasticizers; white oils. An arrangement concerning this is based on expert knowledge as set forth for example in Fiedler, H.P., Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete [Dictionary of Excipients for Pharmacy, Cosmetics and Associated Fields], 4th edition, Aulendorf: ECV-Editio-Cantor-Verlag, 1996.

The following examples serve to illustrate the invention without limiting it.

The nuclear magnetic resonance spectral properties (NMR) relate to chemical shifts (δ) expressed in parts per million (ppm). The relative area for the shifts in the ^1H NMR spectrum corresponds to the number of hydrogen atoms for a particular functional type in the molecule. The nature of the shift in terms of multiplicity is indicated as singlet (s), broad singlet (s. br.), doublet (d), broad doublet (d br.), triplet (t), broad triplet (t br.), quartet (q), quintet (quint.), multiplet (m).

A) Preparation Examples:

Example 1

2-(3-{4-[2-*tert*-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl}propyl)-3,4-dihydro-1*H*-2-benzazepine-1,5(2*H*)-dione

3,4-Dihydro-1*H*-2-benzazepine-1,5(2*H*)-dione (2.85 mmol, 0.50 g; prepared according to Tetrahedron Lett. 1993, 34, 5855) in dimethylformamide (5 ml) was added at 10°C to a suspension of sodium hydride (3.40 mmol, 0.13 g, 60%, deoiled) in dimethylformamide (10 ml), and the mixture was stirred at room temperature for 1 h. Subsequently, 2-*tert*-butyl-4-[4-(3-chloropropyl)piperazin-1-yl]-6-(trifluoromethyl)-pyrimidine (3.00 mmol, 1.09 g; prepared according to WO 99/02503) in dimethylformamide (5 ml) was added dropwise. The reaction mixture was stirred further at room temperature for 12 h. The oil remaining after the evaporative concentration was taken up in a 1:1 mixture of ethyl acetate and water, extracted and washed with a saturated aqueous sodium chloride solution. The organic phase was dried over sodium sulfate and concentrated. The residue was purified by chromatography on silica gel (eluent: 95:5 v/v dichloromethane:methanol).

The second fraction obtained was the title compound, 2-(3-{4-[2-*tert*-butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl}propyl)-3,4-dihydro-1*H*-2-benzazepine-1,5(2*H*)-dione, in a yield of 20 mg.

ESI-MS: $[\text{M}+\text{Na}^+]$ = 526.2, 505.2, $[\text{M}+\text{H}^+]$ = 504.2, 252.6;

^1H NMR (400 MHz, CDCl_3) δ (ppm): 7.90 (1H, d), 7.68-7.54 (3H, m), 6.57 (1H, s), 3.77-

3.65 (8H, m), 2.99 (2H, m sym.), 2.53 (4H, t), 2.47 (2H, t), 1.89 (2H, quint.), 1.33 (9H, s).

Example 2

- 5 1-(3-{4-[2-*tert*-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl}propyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

Analogously to Example 1, 30.0 mg of the title compound were obtained from 3,4-dihydro-1*H*-1-benzazepine-2,5-dione (2.85 mmol, 0.50 g; preparation according to
10 Arch. Pharm. 1991, 324, 579).

¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.59-7.53 (2H, m), 7.33-7.24 (2H, m), 6.53 (1H, s), 3.96 (2H, s br.), 3.59 (4H, s br.), 3.02-2.92 (2H, m), 2.81 (2H, t), 2.36 (4H, t), 2.28 (2H, t), 1.73 (2H, quint.), 1.32 (9H, s).

15

Example 3:

1-(4-{4-[2-*tert*-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl}butyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

- 20 a) 1-(4-Chlorobutyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

Analogously to the procedure described in Example 1, reaction of 3,4-dihydro-1*H*-1-benzazepine-2,5-dione (11.42 mmol, 2.00 g) and bromo-4-chlorobutane (13.7 mmol, 2.35 g) afforded 1.78 g of the title compound, contaminated with reactants to an extent
25 of 30%. The mixture thus obtained was reacted without further purification.

b) 1-(4-{4-[2-*tert*-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl}butyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

- 30 1-(4-Chlorobutyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione (3.29 mmol, 1.75 g, 70%), 2-*tert*-butyl-4-piperazin-1-yl-6-(trifluoromethyl)pyrimidine (3.56 mmol, 1.03 g; preparation according to WO 99/02503) and triethylamine (13.17 mmol, 1.33 g) in dimethylformamide (100 ml) were stirred at 100°C for 12 h. Afterward, ethyl acetate was added and the mixture was washed twice with water. The combined organic phases were
35 dried over Na₂SO₄, filtered and concentrated under reduced pressure. The oily residue was purified by chromatography on silica gel (eluent: 95:5 v/v dichloromethane:methanol); yield 0.42 g.

ESI-MS: 519.2, [M+H⁺] = 518.2, 259.6;

57

¹H NMR (500 MHz, CDCl₃) δ (ppm): 7.57-7.52 (2H, m), 7.29 (1H, t), 7.25 (1H, d+CHCl₃), 6.57 (1H, s), 3.92 (2H, s br.), 3.63 (4H, s br.), 3.01-2.95 (2H, m), 2.80 (2H, t), 2.41 (4H, t), 2.28 (2H, t), 1.53 (2H, quint.), 1.42 (2H, quint.), 1.34 (9H, s).

5 Example 4:

1-((2*E*)-4-{4-[2-*tert*-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl}but-2-enyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

10 Analogously to Example 1, 0.78 g of the title compound was obtained from 3,4-dihydro-1*H*-1-benzazepine-2,5-dione (4.42 mmol, 0.78 g; preparation according to Arch. Pharm. 1991, 324, 579) and 2-*tert*-butyl-4-{4-[(2*E*)-4-chlorobut-2-en-1-yl]piperazin-1-yl}-6-(trifluoromethyl)pyrimidine (4.64 mmol, 1.75 g, preparation according to WO 99/02503).

15 ESI-MS: 517.3, [M+H⁺] = 516.3, 258.6;

¹H NMR (500 MHz, CDCl₃) δ (ppm): 7.53 (1H, d), 7.48 (1H, t), 7.27-7.21 (m+CHCl₃), 6.56 (1H, s), 5.60 (2H, m sym.), 4.45 (2H, m), 3.64 (4H, s br.), 3.02-2.94 (4H, m), 2.84 (2H, t), 2.35 (4H, t), 1.35 (9H, s).

20 Example 5:

2-(4-{4-[2-*tert*-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl}butyl)-3,4-dihydro-1*H*-2-benzazepine-1,5(2*H*)-dione

a) 2-(4-Chlorobutyl)-3,4-dihydro-1*H*-2-benzazepine-1,5(2*H*)-dione

25

Analogously to Example 3a, 1.04 g of the title compound contaminated with reactant to an extent of 50% were obtained from 3,4-dihydro-1*H*-2-benzazepine-1,5(2*H*)-dione and bromo-4-chlorobutane (13.7 mmol, 2.35 g). The substance was reacted without further purification.

30

b) 2-(4-{4-[2-*tert*-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl}butyl)-3,4-dihydro-1*H*-2-benzazepine-1,5(2*H*)-dione

35 The preparation was analogous to Example 3b. 0.15 g of the title compound was obtained from 2-(4-chlorobutyl)-3,4-dihydro-1*H*-2-benzazepine-1,5(2*H*)-dione (1.88 mmol, 1.00 g).

ESI-MS:[M+Na⁺] = 540.3, 519.3, [M+H⁺] = 518.3, 259.6.

40 Example 6:

58

1-(4-{4-[2-*tert*-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl}butyl)-7,8-dimethoxy-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

a) 1-(4-Chlorobutyl)-7,8-dimethoxy-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

5

Analogously to Example 1, reaction of 7,8-dimethoxy-3,4-dihydro-1*H*-1-benzazepine-2,5-dione (1.70 mmol, 0.40 g, preparation according to Arch. Pharm. 1991, 324, 579) and bromo-4-chlorobutane (2.04 mmol, 0.35 g) afforded 0.20 g of the contaminated title compound. The compound is reacted further without purification.

10

b) 1-(4-{4-[2-*tert*-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl}butyl)-7,8-dimethoxy-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

Reaction of 1-(4-chlorobutyl)-7,8-dimethoxy-3,4-dihydro-1*H*-1-benzazepine-2,5-dione (0.49 mmol, 0.20 g) analogously to Example 3b afforded 0.12 g of the title compound.

15

ESI-MS: 579.2, $[M+H]^+$ = 578.3;

¹H NMR (500 MHz, CDCl₃) δ (ppm): 7.09 (1H, s), 6.68 (1H, s), 6.56 (1H, s), 3.94 (3H, s), 3.92 (3H, s), 3.65 (4H, s br.), 2.97-2.92 (2H, m), 2.79 (2H, m br.), 2.40 (4H, t), 2.29 (2H, t), 1.49 (2H, quint.), 1.41 (2H, quint.), 1.31 (9H, s).

20

Example 7:

1-{4-[4-(2-*tert*-Butyl-6-propylpyrimidin-4-yl)piperazin-1-yl]butyl}-3,4-dihydro-1*H*-1-benzazepine-2,5-dione hydrochloride

25

Analogously to Example 3b, reaction of 2-*tert*-butyl-4-piperazin-1-yl-6-propylpyrimidine (2.68 mmol, 0.70 g) with 1-(4-chlorobutyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione affords the free base of the title compounds. Subsequent reaction of the free base with HCl afforded 0.39 g of the title compound as the hydrochloride.

30

ESI-MS: 493.5, $[M+H]^+$ = 492.5, 246.7;

¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.56-7.49 (3H, m), 7.31-7.18 (2H+CHCl₃, m), 6.10 (1H, s), 3.92 (2H, t br.), 3.58 (4H, s br.), 3.02-2.94 (2H, m), 2.81 (2H, t), 2.53 (2H, t), 2.40 (4H, s br.), 2.28 (2H, t), 1.72 (1H, q), 1.51 (2H, quint.), 1.43 (2H, quint.), 1.33 (9H, s), 0.92 (1H, t).

35

Example 8:

1-{4-[4-(2-*tert*-Butyl-6-cyclobutylpyrimidin-4-yl)piperazin-1-yl]butyl}-3,4-dihydro-1*H*-1-benzazepine-2,5-dione hydrochloride

40

59

Analogously to Example 3b, reaction of 2-*tert*-butyl-4-cyclobutyl-6-piperazin-1-ylpyrimidine (1.97 mmol, 0.54 g) with 1-(4-chlorobutyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione afforded 0.39 g of the title compound.

5 ESI-MS: $[M+H]^+$ = 504.5, 252.9.

Example 9:

1-{4-[4-(2-*tert*-Butyl-6-methylpyrimidin-4-yl)piperazin-1-yl]butyl}-3,4-dihydro-1*H*-1-benzazepine-2,5-dione hydrochloride

10

Analogously to Example 3b, reaction of 2-*tert*-butyl-4-methyl-6-piperazin-1-ylpyrimidine (1.97 mmol, 0.46 g) with 1-(4-chlorobutyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione afforded 0.31 g of the title compound.

15 ESI-MS: $[M+H]^+$ = 464.4, 232.6.

Example 10:

1-{4-[4-(2,6-Di-*tert*-butylpyrimidin-4-yl)piperazin-1-yl]butyl}-3,4-dihydro-1*H*-1-benzazepine-2,5-dione hydrochloride

20

Analogously to Example 3b, reaction of 2,4-di-*tert*-butyl-6-piperazin-1-ylpyrimidine (1.26 mmol, 0.35 g) with 1-(4-chlorobutyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione afforded 0.04 g of the title compound.

25 ESI-MS: $[M+H]^+$ = 506.4, 233.8

Example 11:

1-{4-[4-(2-*tert*-Butyl-6-isopropylpyrimidin-4-yl)piperazin-1-yl]butyl}-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

30

Analogously to Example 3b, reaction of 2-*tert*-butyl-4-isopropyl-6-piperazin-1-ylpyrimidine (0.95 mmol, 0.25 g) with 1-(4-chlorobutyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione afforded 0.04 g of the title compound.

35 ESI-MS: $[M+H]^+$ = 492.5, 246.7.

Example 12:

1-(5-{4-[2-*tert*-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl}pentanoyl)-1,2,3,4-tetrahydro-5*H*-1-benzazepin-5-one

40

a) 1-(5-Chloropentanoyl)-1,2,3,4-tetrahydro-5*H*-1-benzazepin-5-one

60

5-Chlorovaleryl chloride (18.61 mmol, 2.89 g) in dimethylformamide (20 ml) was added dropwise at 10° to a suspension of 1,2,3,4-tetrahydro-5*H*-1-benzazepin-5-one (12.41 mmol, 2.00 g, preparation according to J. Org. Chem 1972, 37, 2849) and potassium carbonate (14.89 mmol, 2.06 g) in dimethylformamide (40 ml). The reaction mixture was stirred first at 10°C for 1 h and then under reflux for 3 h. The precipitated salts were filtered off and the filtrate was concentrated to dryness. CH₂Cl₂ was added to the oil obtained in this way and the mixture was washed three times with 50 ml each time of a 5% aqueous sodium hydrogencarbonate solution, neutralized with 0.1N HCl (20 ml) and then washed three times with a saturated sodium chloride solution. The organic phase was dried over Na₂SO₄ and concentrated under reduced pressure; yield 3.90 g (80% pure).

ESI-MS: [M+H⁺] = 280.1;

b) 1-(5-{4-[2-*tert*-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl}pentanoyl)-1,2,3,4-tetrahydro-5*H*-1-benzazepin-5-one

1-(5-Chloropentanoyl)-1,2,3,4-tetrahydro-5*H*-1-benzazepin-5-one from Example 12a (1.43 mmol, 0.50 g), 2-*tert*-butyl-4-piperazin-1-yl-6-(trifluoromethyl)pyrimidine (1.43 mmol, 0.41g, preparation according to DE 19735410), NaBr (7.14 mmol, 0.74 g), DIPEA (diisopropylethylamine) (14.01 mmol, 1.81 g) and N-methylpyrrolidinone (0.6 ml) were heated to 120°C for 5 h. Subsequently, the reaction mixture was filtered and the resulting filtrate was concentrated to dryness. Afterward, ethyl acetate was added to the resulting residue and it was washed with saturated, aqueous sodium chloride solution. The organic phase was dried and then concentrated to dryness. The residue was purified by chromatography on silica gel, eluent: methyl *tert*-butyl ether/methanol (0-100%); to obtain 0.31 g of the title compound.

ESI-MS: [M+H⁺] = 532.7, 267.0.

Example 13:

1-{5-[4-(2-*tert*-Butyl-6-propylpyrimidin-4-yl)piperazin-1-yl]pentanoyl}-1,2,3,4-tetrahydro-5*H*-1-benzazepin-5-one hydrochloride

Analogously to the method for Example 12b, 0.40 g of the title compound was obtained from 1-(5-chloropentanoyl)-1,2,3,4-tetrahydro-5*H*-1-benzazepin-5-one (1.61 mmol, 0.50 g) and 2-*tert*-butyl-4-piperazin-1-yl-6-propylpyrimidine (1.61 mmol, 0.42 g, preparation according to DE 19735410).

ESI-MS: [M+H⁺] = 506.4, 253.6.

Example 14:

1-(4-{4-[2-*tert*-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl}butanoyl)-1,2,3,4-tetrahydro-5*H*-1-benzazepin-5-one

5 a) 1-(4-Chlorobutyryl)-1,2,3,4-tetrahydrobenzo[b]azepin-5-one

Analogously to the method for Example 12a, 0.24 g of 1-(4-chlorobutyryl)-1,2,3,4-tetrahydrobenzo[b]azepin-5-one was obtained from 1,2,3,4-tetrahydro-5*H*-1-benzazepin-5-one (1.24 mmol, 0.20 g, preparation according to J. Org. Chem 1972, 37, 2849) and
10 4-chlorobutyryl chloride (1.86 mmol, 0.27 g) in dioxane (10 ml).

b) 1-(4-{4-[2-*tert*-Butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl}butanoyl)-1,2,3,4-tetrahydro-5*H*-1-benzazepin-5-one

15 Analogously to the method for Example 12b, 0.40 g of the title compound was obtained from 1-(4-chlorobutyryl)-1,2,3,4-tetrahydrobenzo[b]azepin-5-one (0.45 mmol, 0.12 g) from Example 14a and 2-*tert*-butyl-4-piperazin-1-yl-6-(trifluoromethyl)pyrimidine (0.45 mmol, 0.12, prepared according to DE 19735410).

20 ESI-MS: $[M+H]^+$ = 518.3, 259.6.

Example 15:

1-(4-{4-[2-*tert*-Butyl-6-propylpyrimidin-4-yl]piperazin-1-yl}butyryl)-1,2,3,4-tetrahydrobenzo[b]azepin-5-one

25

Analogously to the method for Example 12b, 85.0 mg of the title compound are obtained from 1-(4-chlorobutyryl)-1,2,3,4-tetrahydrobenzo[b]azepin-5-one from Example 14a (0.45 mmol, 0.12 g) and 2-*tert*-butyl-4-piperazin-1-yl-6-propylpyrimidine (0.45 mmol, 0.12 g, prepared according to DE 19735410).

30

ESI-MS: $[M+H]^+$ = 492.4, 246.7.

Example 16:

1-(4-{4-[2-*tert*-Butyl-6-cyclopropylpyrimidin-4-yl]piperazin-1-yl}butyl)-3,4-dihydro-1*H*-benzo[b]azepine-2,5-dione

35

Analogously to the method for Example 12b, 45.0 mg of the title compound are obtained from 1-(4-chlorobutyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione from Example 3a (0.38 mmol, 0.10 g) and 2-*tert*-butyl-4-cyclopropyl-6-piperazin-1-ylpyrimidine
40 (0.40 mmol, 0.05 g; prepared according to DE 19728996).

ESI-MS: $[M+H]^+$ = 490.4, 245.7.

Example 17:

1-{4-[4-(2-*tert*-Butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-1-yl]butyl}-1H-quinoline-
5 2,4-dione trifluoroacetate

a) 1-(4-Chlorobutyl)-4-hydroxy-1H-quinolin-2-one

10 Analogously to the procedure described in Example I, reaction of 4-hydroxy-1H-quinolin-2-one (24.82 mmol, 4.00 g, prepared according to Monatsh. Chem. 1965, 96, 418) and bromo-4-chlorobutane (29.78 mmol, 5.11 g) afforded 6.70 g of the title compound which is contaminated with reactant. The mixture thus obtained was used in the next step without further purification.

15 b) 1-{4-[4-(2-*tert*-Butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-1-yl]butyl}-1H-quinoline-2,4-dione

Analogously to the method from Example 3b, 3.20 g of the title compound were obtained from 1-(4-chlorobutyl)-4-hydroxy-1H-quinolin-2-one from Example 17a (4.00 g).

20

ESI-MS: $[M+Na]^+$ = 526.5, 505.5, $[M+H]^+$ = 504.5, 454.5, 252.7;

¹H NMR (500 MHz, CDCl₃) δ (ppm): 11.75 (1H, s br.), 7.85 (1H, d), 7.42 (t, 1H), 7.26-7.20 (2H+CHCl₃, m), 6.66 (1H, s.), 5.98 (1H, s), 4.18 (2H, m sym.), 3.29 (2H, m sym.), 2.21 (2H, quint.), 2.04 (2H, quint.), 1.33 (9H, s).

25

Example 18:

1-[4-(7-Propionyl-3,4-dihydroisoquinolin-2(1H)-yl)butyl]-3,4-dihydro-1H-1-benzazepine-
2,5-dione

30 a) 2-(Trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline:

Trifluoroacetic anhydride (2.13 mol, 452.0 g) was initially charged in dichloromethane (452 ml) at 10 – 15°C. A solution of tetrahydroisoquinoline (1.94 mol, 268.3 g) in dichloromethane (90 ml) was added thereto at this temperature. The reaction mixture
35 was stirred further at room temperature overnight and then hydrolyzed with ice-water (813 g). After stirring for 1 h, the phases were separated. The organic phase was washed successively with water (813 ml), with semiconcentrated NaHCO₃ solution (550 ml) and again with water (500 ml). Subsequently, the mixture was concentrated under reduced pressure to obtain 446 g of crude product which was used in the subse-
40 quent reaction.

b) 1-[2-(Trifluoroacetyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]propan-1-one

- Aluminum trichloride (0.78 mol, 103.7 g) was suspended in dichloromethane (93 ml) at 10–15°C. Subsequently, the trifluoroacetyltetrahydroisoquinoline from step a) (2.13 mol, 452.0 g) and propionyl chloride (0.47 mol, 43.2 g) were added successively with cooling at this temperature. Subsequently, the mixture was heated to reflux (heating bath temperature 60°C; reflux about 43°C) and the heating bath temperature was retained for 5 h. In the course of this, the internal temperature rose slowly from 43°C to 51°C. The mixture was then cooled to 5–10°C and then diluted with 70 ml of dichloromethane. The reaction solution was subsequently introduced rapidly with ice bath cooling into a mixture of 1000 g of ice and 500 ml of methyl tert-butyl ether. After 30 min, the phases were separated and the organic phase was washed successively with 500 ml of water, with 500 ml of semiconcentrated NaHCO₃ solution and again with 300 ml of water. The organic phase was subsequently concentrated under reduced pressure to obtain 89.9 g of a mixture of the title compound with its 6-isomer (7-isomer:6-isomer isomeric ratio: about 75:25 (by means of ¹³C NMR)) which was used in the next stage.

c) 7-Propionyl-1,2,3,4-tetrahydroisoquinoline (hydrochloride)

- The product from step b) (0.39 mol, 111.0 g) was dissolved in n-propanol (744 ml) and hydrochloric acid (32%, 3.5 mol, 400 g) was added thereto. Subsequently, the mixture was heated to reflux for 5 h. Afterward, a further 300 ml of n-propanol were added and water was distilled off in an azeotrope with n-propanol. A total of 890 ml of distillate were distilled off. In the course of this, the hydrochloride of the propionylisoquinoline precipitated out; another 1500 ml of n-propanol were added and distilled off again. Subsequently, 1200 ml of methyl tert-butyl ether were added, and the mixture was cooled to 5°C and stirred for 30 min. The resulting solid was filtered off and dried at 40–50°C under reduced pressure. In this way, 82.9 g of a mixture of 6- and 7-propionyl-1,2,3,4-tetrahydroisoquinoline were obtained as the hydrochloride with an isomer ratio of 7-isomer:6-isomer of about 80:20 (determined by means of ¹³C NMR).

d) 1-[4-(7-Propionyl-3,4-dihydroisoquinolin-2(1*H*)-yl)butyl]-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

- Analogously to the method for Example 3b, 0.37 g of the title compound was obtained from 7-propionyl-1,2,3,4-tetrahydroisoquinolinium hydrochloride (3.00 mmol, 0.68 g).

ESI-MS: [M+Na⁺] = 441.4, 420.4, [M+H⁺] = 419.4.

40 Example 19:

1-[4-(6-Chloro-1,2,4,5-tetrahydro-3*H*-3-benzazepin-3-yl)butyl]-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

Analogously to Example 3b, reaction of 6-chloro-2,3,4,5-tetrahydro-1*H*-3-benzazepinium-(2*E*)-3-carboxyacrylate (0.95 mmol, 0.28 g, preparation according to J. Med. Chem. 1990, 33, 633) with 1-(4-chlorobutyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione afforded 13.0 mg of the title compound.

ESI-MS: 414.2, 413.1, $[M+H^+] = 411.2$.

Example 20:

2-[4-(2,5-Dioxo-2,3,4,5-tetrahydro-1*H*-1-benzazepin-1-yl)butyl]-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile trifluoroacetate

Analogously to the method for Example 3b, reaction of 1,2,3,4-tetrahydroisoquinoline-6-carbonitrile (0.94 mmol, 0.15 g, preparation according to J. Med. Chem. 2000, 43, 1878) with 1-(4-chlorobutyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione afforded 26.5 mg of the title compound.

ESI-MS: 389.2, $[M+H^+] = 388.1$.

Example 21:

1-[4-(4-Methylpiperazin-1-yl)butyl]-3,4-dihydro-1*H*-1-benzazepine-2,5-dione hydrochloride

Analogously to the method for Example 3b, 0.02 g of the title compound was obtained from 1-methylpiperazine (1.23 mmol, 0.12 g).

ESI-MS: $[M+H^+] = 330.2$.

Example 22:

1-[4-(4-Ethylpiperazin-1-yl)butyl]-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

Analogously to the method for Example 3b, 0.01 g of the title compound was obtained from 1-ethylpiperazine (1.26 mmol, 0.14 g).

ESI-MS: $[M+H^+] = 344.3$.

Example 23:

1-[4-(4-Isobutylpiperazin-1-yl)butyl]-3,4-dihydro-1*H*-1-benzazepine-2,5-dione hydrochloride

65

Analogously to the method for Example 3b, 0.13 g of the title compound was obtained from 1-isobutylpiperazine (0.97 mmol, 0.14 g).

ESI-MS: $[M+H]^+$ = 372.4, 186.8;

- 5 1H NMR (400 MHz, $CDCl_3$) δ (ppm): 7.58-7.51 (2H, m), 7.32-7.23 (m, 2H+ $CHCl_3$), 3.87 (2H, t), 2.97 (2H, m), 2.78 (2H, t), 2.40 (s br.), 2.25 (2H, t), 2.06 (2H, d), 1.75 (1H, sept.), 1.50 (2H, quint.).

Example 24:

- 10 1-[4-(2,4,6-Trimethylpiperazin-1-yl)butyl]-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

Analogously to the method for Example 3b, 0.08 g of the title compound was obtained from 1,3,5-trimethylpiperazine (0.97 mmol, 0.12 g).

- 15 ESI-MS: $[M+H]^+$ = 358.3, 179.1, 157.1, 129.1.

Example 25:

1-[4-(4-Propylpiperazin-1-yl)butyl]-3,4-dihydro-1*H*-benzo[b]azepine-2,5-dione

- 20 Analogously to the method for Example 12b, 0.10 g of the title compound was obtained from 1-(4-chlorobutyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione (0.50 mmol, 0.13 g) and 1-propylpiperazine dihydrobromide (0.47 mmol, 0.14 g).

ESI-MS: $[M+H]^+$ = 358.3;

- 25 1H NMR (400 MHz, $CDCl_3$) δ (ppm): 7.58-7.50 (2H, m), 7.33-7.21 (2H+ $CHCl_3$, m), 3.87 (t, 2H), 2.95 (2H, t), 2.79 (2H, t), 2.41 (8H, s br.), 2.27 (2H, quart.), 1.49 (2H, quint.), 1.39 (2H, quint.), 0.89 (3H, t).

Example 26:

- 30 1-[4-((*R*)-3-Methylpiperazin-1-yl)butyl]-3,4-dihydro-1*H*-benzo[b]azepine-2,5-dione

Analogously to the method for Example 12b, 0.07 g of the title compound was obtained from 1-(4-chlorobutyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione (0.56 mmol, 0.15 g) and (*R*)-(-)-2-methylpiperazine (0.54 mmol, 0.05 g).

35

ESI-MS: $[M+H]^+$ = 330.1.

Example 27:

- 40 1-[4-(4-Ethyl-(*R*)-3-methylpiperazin-1-yl)butyl]-3,4-dihydro-1*H*-benzo[b]azepine-2,5-dione

30.0 mg of the title compound were obtained by reductive amination by the method specified by A. Magid et al. in Tetrahedron Lett. 31 (1990), p. 5595 from 1-[4-((R)-3-methylpiperazin-1-yl)butyl]-3,4-dihydro-1H-benzo[b]azepine-2,5-dione from Example 26 (0.18 mmol, 60.0 mg) and acetaldehyde (0.18 mmol, 8.0 mg).

5

ESI-MS: $[M+H]^+ = 358.3$;

1H NMR (400 MHz, $CDCl_3$) δ (ppm): 7.60-7.46 (2H, m), 7.35-7.14 (2H+ $CHCl_3$, m), 3.87 (t, 2H), 2.97 (2H, t), 2.92-2.74 (4H, m), 2.71 (1H, d), 2.61 (1H, d), 2.50-2.03 (6H, m incl. 2.22 (2H, t)), 1.84 (1H, s br.), 1.50 (2H, quint.), 1.38 (2H, quint.), 1.14-0.91 (6H, m).

10

Example 28:

1-[4-((S)-3-Methylpiperazin-1-yl)butyl]-3,4-dihydro-1H-benzo[b]azepine-2,5-dione

15

Analogously to the method for Example 12b, reaction of 1-(4-chlorobutyl)-3,4-dihydro-1H-1-benzazepine-2,5-dione (0.56 mmol, 0.15 g) with (S)-(+)-2-methylpiperazine (0.54 mmol, 0.05 g) afforded 40.0 mg of the title compound.

ESI-MS: $[M+H]^+ = 330.2$.

20

Example 29:

1-[4-(4-Ethyl-(S)-3-methylpiperazin-1-yl)butyl]-3,4-dihydro-1H-benzo[b]azepine-2,5-dione

25

Analogously to the method from Example 27, reductive amination afforded 10.0 mg of the title compound from 1-[4-((S)-3-methylpiperazin-1-yl)butyl]-3,4-dihydro-1H-benzo[b]azepine-2,5-dione from Example 28 (0.12 mmol, 40.0 mg) and acetaldehyde (0.12 mmol, 5.0 mg).

ESI-MS: $[M+H]^+ = 358.3$.

30

Example 30:

1-[4-(4-Ethylpiperazin-1-yl)-4-oxobutyl]-3,4-dihydro-1H-benzo[b]azepine-2,5-dione

a) Methyl 4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butanoate

35

Analogously to the method for Example 1, 100 mg of the title compound were obtained from 3,4-dihydro-1H-benzo[b]azepine-2,5-dione (5.71, 1.00 g, prepared according to Tetrahedron Lett. 1993, 34, 5855) and methyl 4-iodobutanoate (5.71 mmol, 1.37 g).

40

ESI-MS: $[M+H]^+ = 276.15$;

b) 4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butanoic acid

Methyl 4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butanoate from step a (100 mg, 0.36 mmol) in water/methanol (0.7:2.0 ml) was treated with NaOH (1N, 0.80 ml) to obtain 63.0 mg of 4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butanoic acid.

ESI-MS: $[M+H^+] = 262.0$;

c) 1-[4-(4-ethylpiperazin-1-yl)-4-oxobutyl]-3,4-dihydro-1H-benzo[b]azepine-2,5-dione

On the basis of the method described by M.K. Dhaon et al. in J. Org. Chem. 47 (1982) p. 1962, reaction of 4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butanoic acid (0.06 g) from step b and 1-ethylpiperazine (0.25 mmol, 0.03 g) in the presence of EDC·HCl (N'-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride) (0.36 mmol, 0.07 g), Et₃N (0.48 mmol, 0.05 g) in tetrahydrofuran (5 ml) afforded 10.0 mg of the title compound.

ESI-MS: $[M+H^+] = 358.3$.

The preparation of the compounds of Examples 31 – 60 was based on the above-described methods.

Example 31:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-isopropylpiperazin-1-ium trifluoroacetate

ESI-MS: $[M+H^+] = 358.2$.

Example 32:

4-sec-Butyl-1-[4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]piperazin-1-ium trifluoroacetate

ESI-MS: $[M+H^+] = 372.3$.

Example 33:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-(1-methylbutyl)piperazin-1-ium trifluoroacetate

ESI-MS: $[M+H^+] = 386.1$.

Example 34:

4-Butyl-1-[4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]piperazin-1-ium trifluoroacetate

5 ESI-MS: $[M+H^+] = 372.1$.

Example 35:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-(1-ethylpropyl)piperazin-1-ium trifluoroacetate

10

ESI-MS: $[M+H^+] = 386.1$.

Example 36:

4-Cyclopentyl-1-[4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]piperazin-1-ium trifluoroacetate

15

ESI-MS: $[M+H^+] = 384.4$.

Example 37:

4-Cyclohexyl-1-[4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]piperazin-1-ium trifluoroacetate

20

ESI-MS: $[M+H^+] = 398.5$.

Example 38:

4-(3-Cyclohexylpropyl)-1-[4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]piperazin-1-ium trifluoroacetate

25

ESI-MS: $[M+H^+] = 440.4, 238.9, 211.0$.

30

Example 39:

4-Cyclohexylmethyl-1-[4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]piperazin-1-ium trifluoroacetate

35 ESI-MS: $[M+H^+] = 412.4, 279.0, 183.0$.

Example 40:

4-(2-Cyclohexylethyl)-1-[4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]piperazin-1-ium trifluoroacetate

40

ESI-MS: $[M+H^+] = 426.4, 307.1, 197.0$.

Example 41:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-(tetrahydrofuran-2-ylmethyl)piperazin-1-ium trifluoroacetate

5

ESI-MS: $[M+Na^+] = 422.4$, $[M+H^+] = 400.4$, 170.9 .

Example 42:

4-Benzyl-1-[4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]piperazin-1-ium trifluoroacetate

10

ESI-MS: $[M+H^+] = 406.3$.

Example 43:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-(2-pyrrol-1-yl-ethyl)piperazin-1-ium trifluoroacetate

15

ESI-MS: $[M+H^+] = 409.2$.

Example 44:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-(2-imidazol-1-ylethyl)piperazin-1-ium trifluoroacetate

20

ESI-MS: $[M+Na^+] = 432.0$, $[M+H^+] = 410.0$, 342.0 , 113.0 .

25

Example 45:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-(2-thiophen-2-ylethyl)piperazin-1-ium trifluoroacetate

30

ESI-MS: $[M+H^+] = 426.4$.

Example 46:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-(2-methoxyethyl)piperazin-1-ium trifluoroacetate

35

ESI-MS: $[M+H^+] = 374.2$.

Example 47:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-(3-methoxypropyl)piperazin-1-ium trifluoroacetate

40

ESI-MS: $[M+H]^+ = 388.1$.

Example 48:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-(2-ethoxyethyl)piperazin-
5 1-ium trifluoroacetate

ESI-MS: $[M+Na]^+ = 410.0$, $[M+H]^+ = 388.2$.

Example 49:

10 4-(2-Dimethylaminoethyl)-1-[4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)-
butyl]piperazin-1-ium trifluoroacetate

ESI-MS: $[M+H]^+ = 387.1$, 341.9 .

15 Example 50:

4-(3-Cyanopropyl)-1-[4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]- piper-
azin-1-ium trifluoroacetate

ESI-MS: $[M+Na]^+ = 405.0$, $[M+H]^+ = 383.1$, 153.9 .

20

Example 51:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-(2-oxo-2-pyrrolidin-1-
ylethyl)piperazin-1-ium trifluoroacetate

25 ESI-MS: $[M+Na]^+ = 449.0$, $[M+H]^+ = 427.1$, 197.9 .

Example 52:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-(2-morpholin-4-yl-2-
oxoethyl)piperazin-1-ium trifluoroacetate

30

ESI-MS: $[M+Na]^+ = 465.0$, $[M+H]^+ = 443.2$.

Example 53:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-(2-oxo-2-piperidin-1-
ylethyl)piperazin-1-ium trifluoroacetate

35

ESI-MS: $[M+Na]^+ = 463.1$, $[M+H]^+ = 441.3$.

Example 54:

40 4-Cyclopropanecarbonyl-1-[4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)-
butyl]piperazin-1-ium trifluoroacetate

ESI-MS: $[M+Na]^+$ = 405.9, $[M+H]^+$ = 384.2, 127.9.

Example 55:

- 5 4-Acetyl-1-[4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]piperazin-1-ium trifluoroacetate

ESI-MS: $[M+H]^+$ = 358.0.

- 10 Example 56:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-(tetrahydrofuran-2-carbonyl)piperazin-1-ium trifluoroacetate

ESI-MS: $[M+Na]^+$ = 436.1, $[M+H]^+$ = 414.2, 315.9.

15

Example 57:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-(furan-2-carbonyl)-piperazin-1-ium trifluoroacetate

- 20 ESI-MS: $[M+H]^+$ = 410.2.

Example 58:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-ethanesulfonylpiperazin-1-ium trifluoroacetate

25

ESI-MS: $[M+Na]^+$ = 430.0, $[M+H]^+$ = 408.0.

Example 59:

- 30 1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-methyl[1,4]diazepan-1-ium trifluoroacetate

ESI-MS: $[M+H]^+$ = 344.0.

Example 60:

- 35 1-[4-(4-Allylpiperazin-1-yl)butyl]-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

Analogously to the method for Example 3b, 0.08 g of the title compound was obtained from 1-allylpiperazinediium dichloride (0.97 mmol, 0.19 g).

- 40 ESI-MS: $[M+H]^+$ = 356.3, 178.6;

72

¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.53 (2H, t), 7.39-7.18 (m, 2H+CHCl₃), 5.85 (1H, sext.), 5.15 (2H, t), 3.87 (2H, t), 2.98 (4H, m), 2.79 (2H, t), 2.42 (6H, s br.), 2.27 (2H, t), 1.50 (2H, quint.), 1.39 (2H, quint.).

5 Example 61:

tert-Butyl 4-[4-(2,5-dioxo-2,3,4,5-tetrahydro-1*H*-1-benzazepin-1-yl)butyl]piperazine-1-carboxylate

10 Analogously to the method for Example 3b, 3.44 g of the title compound were obtained from *tert*-butyl piperazine-N-carboxylate (10.01 mmol, 1.86 g)

ESI-MS: [M+H⁺] = 416.2;

15 ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.53 (2H, t), 7.37-7.20 (m, 2H+CHCl₃), 3.88 (2H, t), 3.37 (4H, t), 2.96 (2H, t), 2.80 (2H, t), 2.36-2.16 (6H, m), 1.57-1.32 (13H, m incl. 1.47, s, 9H).

Example 62:

1-(4-Piperazin-1-ylbutyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

20 *tert*-Butyl 4-[4-(2,5-dioxo-2,3,4,5-tetrahydro-1*H*-1-benzazepin-1-yl)butyl]piperazine-1-carboxylate from Example 61 (8.28 mmol, 3.44 g) in diethyl ether (40 ml) was admixed with saturated ethereal HCl (30 ml) and the mixture was stirred at room temperature for 12 h. The reaction mixture was then filtered and the resulting residue was washed with diethyl ether to obtain 0.93 g of the title compound.

25

ESI-MS: [M+H⁺] = 316.1, 158.6;

¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.52 (2H, t), 7.29-7.18 (m, 2H+CHCl₃), 3.91 (2H, t), 2.91 (2H, m), 2.78 (4H, t), 2.73 (2H, t), 2.26 (4H, s br.), 2.17 (2H, t), 1.73 (1H, s br.), 1.46 (2H, quint.), 1.35 (2H, quint.).

30

Example 63:

1-{4-[(1*S*,4*S*)-5-Methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]butyl}-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

35 Analogously to the method for Example 3b, 0.01 g of the title compound was obtained from (1*S*,4*S*)-5-methyl-5-aza-2-azoniabicyclo[2.2.1]heptane trifluoroacetate (0.56 mmol, 0.21 g).

ESI-MS: 343.2, [M+H⁺] = 342.2, 171.6.

40

Example 64

73

1-[4-(Hexahydropyrrolo[1,2-a]pyrazin-2(1*H*)-yl)butyl]-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

- 5 Analogously to the method for Example 12b, reaction of 1-(4-chlorobutyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione (0.40 mmol, 0.11 g) and octahydropyrrolo[1,2-a]pyrazine (0.40 mmol, 0.05 g) afforded 0.05 g of the title compound.

ESI-MS: 357.2, [M+H⁺] = 356.3, 178.6.

10 Example 65:

Benzyl (1*R*,5*R*)-6-[4-(2,5-dioxo-2,3,4,5-tetrahydro-1*H*-1-benzazepin-1-yl)butyl]-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate

- 15 Analogously to the method for Example 12b, 0.22 g of the title compound were obtained from benzyl (1*R*,5*R*)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate (1.43 mmol, 0.33g, prepared according to WO 01/81347).

ESI-MS: [M+H⁺] = 462.3.

20 Example 66

1-{4-[(1*R*,5*R*)-3,6-Diazabicyclo[3.2.0]hept-6-yl]butyl}-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

- 25 In the presence of Pd/C (0.01g, 10%), benzyl (1*R*,5*R*)-6-[4-(2,5-dioxo-2,3,4,5-tetrahydro-1*H*-1-benzazepin-1-yl)butyl]-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate from Example 65 (0.45 mmol, 0.21 g) in methanol (7 ml) was reacted with hydrogen to obtain 0.10 g of the title compound.

Example 67:

- 30 Benzyl (1*S*,5*S*)-6-[4-(2,5-dioxo-2,3,4,5-tetrahydro-1*H*-1-benzazepin-1-yl)butyl]-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate

- 35 Analogously to Example 3b, 0.21 g of the title compound was obtained from benzyl (1*S*,5*S*)-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate (1.42 mmol, 0.33 g, prepared according to WO 01/81347).

ESI-MS: [M+H⁺] = 462.3.

Example 68:

- 40 1-{4-[(1*S*,5*S*)-3,6-Diazabicyclo[3.2.0]hept-6-yl]butyl}-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

On the basis of the method for Example 66, hydrogenation of benzyl (1*S*,5*S*)-6-[4-(2,5-dioxo-2,3,4,5-tetrahydro-1*H*-1-benzazepin-1-yl)butyl]-3,6-diazabicyclo[3.2.0]heptane-3-carboxylate from Example 67 (0.46 mmol, 0.21 g) afforded 0.12 g of the title compound.

Example 69:

1-{4-[(1*S*,5*S*)-3-Ethyl-3,6-diazabicyclo[3.2.0]hept-6-yl]butyl}-3,4-dihydro-1*H*-1-benzazepine-2,5-dione

10

Analogously to the method in Example 27, reductive amination of 1-{4-[(1*S*,5*S*)-3,6-diazabicyclo[3.2.0]hept-6-yl]butyl}-3,4-dihydro-1*H*-1-benzazepine-2,5-dione from Example 68 (0.21 mmol, 0.07 g) and acetaldehyde (0.21 mmol, 9 mg) afforded 0.01 g of the title compound.

15

ESI-MS: $[M+H]^+$ = 356.3.

Example 70:

1-{4-[(1*R*,5*R*)-3-Methyl-3,6-diazabicyclo[3.2.0]hept-6-yl]butyl}-3,4-dihydro-1*H*-benzo[b]azepine-2,5-dione

20

Analogously to the method from Example 27, reductive amination of 1-{4-[(1*R*,5*R*)-(3,6-diazabicyclo[3.2.0]hept-6-yl)butyl]-3,4-dihydro-1*H*-benzo[b]azepine-2,5-dione from Example 66 (0.27 mmol, 0.09 g) and formaldehyde (0.30 mmol, 25.0 mg, 37% solution) afforded 0.02 g of the title compound.

25

ESI-MS: $[M+K]^+$ = 380.1, $[M+H]^+$ = 342.3.

Example 71:

tert-Butyl 5-[4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-(3*S*,6*S*)-hexahydropyrrolo[3,4-*c*]pyrrole-2-carboxylate

30

Analogously to the method from Example 12b, reaction of 1-(4-chlorobutyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione (1.14 mmol, 0.30 g) and tert-butyl (3*S*,6*S*)-hexahydropyrrolo[3,4-*c*]pyrrole-2-carboxylate (1.08 mmol, 0.23 g; prepared according to WO 01/81347) afforded 0.25 g of the title compound.

35

ESI-MS: $[M+H]^+$ = 442.4;

¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.63-7.50 (2H, m), 7.36-7.17 (2H+ CHCl₃, m), 3.89 (t, 2H), 3.50 (2H, s br.), 3.15 (2H, s br.), 2.95 (2H, m sym.), 2.87-2.69 (4H, m), 2.60 (2H, s br.), 2.41-2.19 (4H, m), 1.77-1.22 (13H, m incl. 1.45 (9H,s)).

40

Example 72:

1-[4-((3S,6S)-Hexahydropyrrolo[3,4-c]pyrrol-2-yl)butyl]-3,4-dihydro-1H-benzo[b]azepine-2,5-dione

5

The reaction of tert-butyl 5-[4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-(3S,6S)-hexahydropyrrolo[3,4-c]pyrrole-2-carboxylate from Example 71 (0.54 mmol, 02.4 g) with trifluoroacetic acid (2.69 ml) gave 0.17 g of the title compound.

10 Example 73:

1-[4-((3S,6S)-5-Methylhexahydropyrrolo[3,4-c]pyrrol-2-yl)butyl]-3,4-dihydro-1H-benzo[b]azepine-2,5-dione

Analogously to the method in Example 27, reductive amination of 1-[4-((3S,6S)-

15 hexahydropyrrolo[3,4-c]pyrrol-2-yl)butyl]-3,4-dihydro-1H-benzo[b]azepine-2,5-dione from Example 72 (0.24 mmol, 82.0 mg) and formaldehyde (0.26 mmol, 21.4 mg, 37% solution) afforded 10.0 mg of the title compound.

¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.61-7.47 (2H, m), 7.39-7.17 (2H+ CHCl₃, m), 3.88
20 (t, 2H), 2.96 (2H, t), 2.80 (4H, t), 2.47-2.17 (7H, m), 1.91-1.14 (10H, m).

Example 74:

1-[4-(Octahydropyrido[1,2-a][1,4]diazepin-2-yl)butyl]-3,4-dihydro-1H-benzo[b]azepine-
2,5-dione

25

Analogously to the method for Example 12b, 65.0 mg of the title compound were obtained from 1-(4-chlorobutyl)-3,4-dihydro-1H-1-benzazepine-2,5-dione (0.75 mmol, 0.20 g) and decahydropyrido[1,2-a][1,4]diazepine (0.75 mmol, 0.12 g; prepared according to *Pol. J. Chem.* 1985, 59, 1243-6).

30

ESI-MS: [M+K⁺] = 422.2, [M+H⁺] = 384.2.

Example 75:

1-{4-[(1S,5R,6S)-6-(4-Fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]butyl}-3,4-dihydro-1H-
35 1-benzazepine-2,5-dione hydrochloride

Analogously to the method for Example 3b, 0.25 g of the title compound was obtained from (1S,5R,6S)-6-(4-fluorophenyl)-3-azabicyclo[3.2.0]heptane (1.97 mmol, 0.38 g, prepared according to WO 00/23423).

40

76

¹H NMR (500 MHz, CDCl₃) δ (ppm): 7.58-7.48 (2H, m), 7.32-7.22 (m+CHCl₃), 7.22-7.12 (2H, m), 6.98 (2H, t), 3.92 (2H, m br.), 3.16 (1H, m br.), 3.06-2.93 (2H, m), 2.93-2.65 (6H, m; incl. t at 2.88), 2.45 (2H, t), 2.16 (2H, t), 2.09-1.92 (2H, m), 1.61 (m+H₂O), 1.49 (2H, quint.).

5

Example 76:

1-(4-Piperidin-1-yl)butyl)-3,4-dihydro-1*H*-1-benzazepine-2,5-dione hydrochloride

10 Analogously to the method for Example 3b, 0.02 g of the title compound was obtained from piperidine (1.24 mmol, 0.11 g).

ESI-MS: [M+H⁺] = 315.2.

In an analogous manner, the compounds of Examples 77 to 82 were prepared.

15

Example 77:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-methylpiperidinium trifluoroacetate

20 ESI-MS: [M+H⁺] = 329.0.

Example 78:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]azepanium trifluoroacetate

25 ESI-MS: [M+H⁺] = 329.0.

Example 79:

1-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-3-methylpiperidinium trifluoroacetate

30

ESI-MS: [M+H⁺] = 329.0.

Example 80:

1-[4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]-4-propylpiperidinium trifluoroacetate

35

ESI-MS: [M+H⁺] = 357.1.

Example 81:

40 4-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]morpholin-4-ium trifluoroacetate

ESI-MS: $[M+H]^+$ = 317.0.

Example 82:

- 5 4-[4-(2,5-Dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]thiomorpholin-4-ium trifluoroacetate

ESI-MS: $[M+H]^+$ = 333.0.

- 10 Example 83:

1-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]-3,4-dihydro-1H-benzo[b]azepine-2,5-dione

- 15 Analogously to Example 3b, reaction of 1-(4-chlorobutyl)-3,4-dihydro-1H-benzo[b]azepine-2,5-dione with 1-(2,3-dichlorophenyl)piperazine afforded the title compound.

ESI-MS: 462.4, $[M+H]^+$ = 461.4, 460.4;

- 20 ^1H NMR (400 MHz, DMSO) δ (ppm): 7.62 (1H, t), 7.51-7.45 (2H, m), 7.34 (1H, t), 7.28 (2H, m), 7.18-7.05 (1H, m), 3.88 (2H, t), 2.91 (6H, m), 2.66 (2H, m), 2.39 (4H, s br.), 2.19 (2H, t), 1.36 (2H, quint.), 1.26 (2H, quint.).

Example 84:

- 25 4-(2,4-Dichlorobenzyl)-1-[4-(2,5-dioxo-2,3,4,5-tetrahydrobenzo[b]azepin-1-yl)butyl]piperazinium as the fumarate

- 30 Analogously to Example 3b, reaction of 1-(4-chlorobutyl)-3,4-dihydro-1H-benzo[b]azepine-2,5-dione with 1-(2,4-dichlorobenzyl)piperazine afforded the title compound.

ESI-MS: 476.1, $[M+H]^+$ = 475.1, 474.1, 237.6;

Example 85:

- 35 1-[4-[4-(2-tert-Butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-1-yl]butyl]azepane-2,5-dione

a) 1-(4-Chlorobutyl)azepane-2,5-dione

- 40 Analogously to Example 3a, 0.17 g of the contaminated title compound was obtained from azepane-2,5-dione (2.36 mmol, 0.30 g, preparation according to J. Photochem. 28 (1985), 569-570) and bromo-4-chlorobutane (2.83 mmol, 0.49 g). The compound is reacted further without purification.

b) 1-{4-[4-(2-tert-Butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-1-yl]butyl}azepane-2,5-dione

- 5 Analogously to Example 3b, 0.04 g of the title compound was obtained from 2-tert-butyl-4-piperazin-1-yl-6-trifluoromethylpyrimidine (0.59 mmol, 0.17 g) and 1-(4-chlorobutyl)azepane-2,5-dione (0.62 mmol, 0.17 g).

ESI-MS: $[M+H]^+$ = 470.2, 235.6;

- 10 ^1H NMR (400 MHz, CDCl_3) δ (ppm): 6.57 (1H, s), 3.71 (4H, s br.), 3.60-3.46 (4H, m), 2.73-2.57 (6H, m), 2.49 (4H, s br.), 2.41 (2H, s br.), 1.33 (9H, s).

Example 86:

- 15 1-{4-[4-(3,5-Dichlorophenyl)-2,5-piperazin-1-yl]butyl}-3,4-dihydro-1H-benzo[b]azepine-2,5-dione fumarate

In analogy to Example 3b, reaction of 1-(4-chlorobutyl)-3,4-dihydro-1H-benzo[b]azepine-2,5-dione with 1-(3,5-dichlorophenyl)piperazine afforded the title
20 compound.

ESI-MS: 462.5, $[M+H]^+$ = 461.5, 460.5;

- 25 ^1H NMR (400 MHz, DMSO) δ (ppm): 7.62 (1H, t), 7.47 (2H, t), 7.35 (1H, t), 6.90 (2H, s), 6.85 (1H, s), 3.88 (2H, m), 3.15 (4H, m), 2.92 (2H, t), 2.67 (2H, t), 2.36 (4H, m), 2.20 (2H, t), 1.35 (2H, quint.), 1.28 (2H, quint.).

Example 87:

1-{4-[4-(3,5-Bis(trifluoromethyl)phenyl)piperazin-1-yl]butyl}-3,4-dihydro-1H-benzo[b]azepine-2,5-dione fumarate

30

In analogy to Example 3b, reaction of 1-(4-chlorobutyl)-3,4-dihydro-1H-benzo[b]azepine-2,5-dione with 1-(3,5-bis(trifluoromethyl)phenyl)piperazine afforded the title compound.

- 35 ESI-MS: $[M+H]^+$ = 528.55;

^1H NMR (400 MHz, DMSO) δ (ppm): 7.64 (1H, t), 7.54-7.41 (4H, m), 7.34 (1H, t), 7.27 (1H, s), 3.88 (2H, m), 3.30 (4H, m br.), 2.91 (2H, t), 2.65 (2H, t), 2.40 (4H, s br.), 2.23 (2H, t), 1.36 (2H, quint.), 1.30 (2H, quint.).

- 40 B) Examples of pharmaceutical administration forms

Tablets:

Tablets of the following composition are compressed in a tablet press in a conventional way:

- 5 40 mg of substance of example 2
120 mg of corn starch
13.5 mg of gelatin
45 mg of lactose
2.25 mg of Aerosil® (chemically pure silica in submicroscopically fine distribution)
10 6.75 mg of potato starch (as 6% strength paste)

Sugar-coated tablets:

- 15 20 mg of substance of example 2
60 mg of core composition
70 mg of sugar-coating composition

- 20 The core composition consists of 9 parts of corn starch, 3 parts of lactose and 1 part of vinylpyrrolidone/vinyl acetate 60:40 copolymer. The sugar-coating composition consists of 5 parts of sucrose, 2 parts of corn starch, 2 parts of calcium carbonate and 1 part of talc. The sugar-coated tablets produced in this way are subsequently provided with an enteric coating.

- 25 C) Biological investigations – receptor binding studies:

The substance to be tested was dissolved either in methanol/Chremophor® (BASF-AG) or in dimethyl sulfoxide and then diluted with water to the desired concentration.

- 30 I. Dopamine D₃ receptor:

- 35 The mixture (0.250 ml) was composed of membranes from ~ 10⁶ HEK-293 cells with stably expressed human dopamine D₃ receptors, 0.1 nM [¹²⁵I]-iodosulpride and incubation buffer (total binding) or with additional test substance (inhibition plot) or 1 µM spiperone (nonspecific binding). Triplicate mixtures were carried out.

- 40 The incubation buffer comprised 50 mM Tris, 120 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 2 mM MgCl₂ and 0.1% bovine serum albumin, 10 µM quinolone, 0.1% ascorbic acid (prepared fresh each day). The buffer was adjusted to pH 7.4 with HCl.

- II. Dopamine D_{2L} receptor:

The mixture (1 ml) was composed of membranes from $\sim 10^6$ HEK-293 cells with stably expressed human dopamine D_{2L} receptors (long isoform) and 0.01 nM [125 I]-iodospiperone and incubation buffer (total binding) or with additional test substance (inhibition plot) or 1 μ M haloperidol (nonspecific binding). Triplicate mixtures were carried out.

The incubation buffer comprised 50 mM Tris, 120 mM NaCl, 5 mM KCl, 2 mM $CaCl_2$, 2 mM $MgCl_2$ and 0.1% bovine serum albumin. The buffer was adjusted to pH 7.4 with HCl.

III. Measurement and evaluation:

After incubation at 25°C for 60 minutes, the mixtures were filtered under vacuum through Whatman GF/B glass fiber filters using a cell harvester. The filters were transferred by a filter transfer system into scintillation vials. After addition of 4 ml of Ultima Gold® (Packard), the samples were shaken for one hour and then the radioactivity was counted in a beta counter (Packard, Tricarb 2000 or 2200CA). The cp values were converted into dpm by means of a standard quench series with the aid of the instrument's own program.

Evaluation of the inhibition plots took place by iterative nonlinear regression analysis using the Statistical Analysis System (SAS) similar to the "LIGAND" program described by Munson and Rodbard.

In these assays, the inventive compounds show very good affinities for the D_3 receptor (< 100 nM, frequently < 50 nM) and bind selectively to the D_3 receptor.

The results of the binding assays are indicated in table 1.

Table 1:

Example	K_i (D_3) [nM]	Selectivity vs. D_{2L}
3	0.83	296
4	1.74	155
6	4.50	104
7	1.33	118
10	1.24	74
16	0.96	62
86	2.0	56
87	7.4	129

* $K_i(D_{2L})/K_i(D_3)$